Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives

Abstract: A serious viral infectious disease was introduced to the globe by the end of 2019 that was seen primarily from China, but spread worldwide in a few months to be a pandemic. Since then, accurate prevention, early detection, and effective treatment strategies are not yet outlined. There is no approved drug to counter its worldwide transmission. However, integration of nanostructured delivery systems with the current management strategies has promised a pronounced opportunity to tackle the pandemic. This review addressed the various promising nanotechnology-based approaches for the diagnosis, prevention, and treatment of the pandemic. The pharmaceutical, pharmacoeconomic, and regulatory aspects of these systems with currently achieved or predicted beneficial outcomes, challenges, and future perspectives are also highlighted.

Keywords: nano-vaccine, nano-theranostics, nanoparticles, nanotechnology, SARS-CoV-2

Introduction
The end of 2019 came with a serious viral infectious disease which was seen primarily from China, but spread worldwide and was declared as a pandemic in a few months. The outbreak officially became a pandemic in March 2020. The World Health Organization (WHO) termed this novel and vastly spreading disease as “coronavirus disease-2019” (COVID-19), and the viral agent as “severe acute respiratory syndrome – coronavirus-2” (SARS-CoV-2). Since then, it has been a massively challenging global epidemic with combined health-related and economic destitution worldwide. SARS-CoV-2 seriously affects the respiratory system by triggering an acute immunological response which is the main cause of death with a fatality rate per country of 0.05–19.4%. The SARS-CoV-2 results in an increased mucous secretion, which then clogs the alveoli and prevents blood oxygenation. Its endocytosis and replication in the lungs generates an acute immune response and tissue inflammation by triggering the signal cascade through cytokine storms. The virus can also spread to the digestive system and other major organs like the kidney and liver. It has the potential to access every tissue that expresses angiotensin-converting enzyme-2 (ACE2) receptor. Structural analyses of SARS-CoV-2 showed that it has spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins which are responsible for its cell attachment and entry mechanisms. Management strategies are based on these structural features. More than 80% of SARS-CoV-2 and host cell membrane interactions occur due to the presence of the...
S protein that is a special characteristic of the pathogenic cell for treatment strategies. Human coronaviruses (HCoVs) are among the top 10 fatal viruses. SARS-CoV, one of the HCoVs, has a mortality rate of up to 10%. Currently, there are approximately 176 million confirmed cases and about 3,811,561 SARS-CoV-2 related deaths worldwide.

Main Symptoms and Related Problems
Fever (85.6%), cough (68.7%), and fatigue (39.4%) are among the major reported symptoms. Dyspnea, headache, loss of appetite, loss of taste and smell, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain are the less common symptoms of the disease. The presence of comorbidities such as hypertension, diabetes, and coronary heart disease may further complicate the problem. There may be a two-week incubation period with mild to moderate symptoms followed by a high infection rate. Reports showed that there are also asymptomatic transmissions. Currently, the viral outbreak has created a global crisis related to disastrous live losses and financial collapses.

Mode of Transmission and Prevention
The two main ways of COVID-19 transmission are direct air-to-air transmission during sneezing, talking, and coughing; and direct contact with contaminated surface/object. Personal hygiene, personal protective equipment (PPE), sanitizers, and surface disinfectants such as ethanol (62–71%), hydrogen peroxide (0.5%), and sodium hypochlorite (0.1%) are the main ways of prevention. Moreover, vaccine and drug development is the most eye-catching option to completely fight COVID-19. There is a continuous global effort to explore and decode the exact genome structure, identify the way of infection and transmission, draw effective prevention and immunomodulation approaches, and develop the most effective therapeutics. However, accurate prevention, early detection, and effective treatment strategies are not yet outlined. There is no approved drug and a free access vaccine to counter its worldwide spread. The various claims on the therapeutic and vaccine development, under various clinical trial phases, did not reach the market yet. At present, the health care and clinical research approaches are being negatively impacted by the pandemic through restrictions in funding and mobility which necessitate innovative life-saving ideas and alternative funding sources.

Diagnostic and Management Approaches
The laboratory diagnosis of this viral infection is based on the techniques like polymerase chain reaction (PCR) and sequencing (smears taken from the oral cavity and throat); computer tomography, which reveals ground-glass opacity in the lungs, indicating viral pneumonia; plain chest radiography which investigates inflammatory foci caused by the virus, fibrosis, and connective tissue occlusions in the lungs that may develop after the disease; ultrasound investigation of the lungs for the visualization of pulmonary and pleural conditions in patients with suspected COVID-19; immunoassays which reveal the substances of protein nature including viruses, and general and biochemical blood test detecting changes in blood parameters related to the infection. Three main steps for an effective management approach considering the interaction of the virus when invading the host cells: cell attachment and entry, replication and protein expression, then finally, assembly, maturation, and exocytosis. Based on this concept, there are four medical approaches: Vaccination, cell entry (cell cycle) inhibition, immune response modulation, and prophylactic treatment.

There are two major drug therapy strategies against the virus: drug repurposing and novel drug discovery. Drug repurposing is trying to combat the pandemic with primarily discovered drugs for other known therapeutic purposes. This is a feasible strategy since it shortens the drug discovery time. In this regard, lidoxyboncin, quinixostat, spirofylne, burixafor, penretexed, edotecarin, diniprofylline, flufoxylne, chloroquine (CQ), hydroxychloroquine (HCQ), remdesivir, tocilizumab, lopinavir/ritonavir, ivermectin, and azithromycin demonstrated potential anti-COVID effects. In addition, combined zinc supplements with CQ, drugs like sibulin and doxepin, and some glucocorticoids (betamethasone, dexamethasone, hydrocortisone, fludrocortisone, ciclosporin, and trimethadione) showed promising effects. Figure 1 demonstrates their mechanism of action and interaction at different stages of the viral cell cycle. Repurposed drugs have previously established safety profiles which facilitate their clinical transition, and result in less risky and more rapid applications. Different in silico tools can be combined with large drug databases for selecting “possible candidates” from the available pharmaceutical and pharmacological substances. Molecular dynamics simulations of HCQ and azithromycin dual therapy demonstrated a promising effectiveness with different potential mechanisms of action against the open and closed viral protein.
forms.\textsuperscript{29–31} HCQ-azithromycin combination approach showed a better clinical outcome in terms of mortality rates among elderly patients, intensive care unit transfers, length of hospital stay, and duration of viral shedding.\textsuperscript{30} A systematic review, meta-analysis, and trial sequential analysis of ivermectin indicated that, using ivermectin for the prevention and treatment of COVID-19 is an equitable, acceptable, and feasible approach. The study strongly suggested that the health professional should consider its use both in therapeutic and prophylaxis approaches.\textsuperscript{32} Remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon beta-1 and CQ or HCQ are being assessed in clinical trials. However, these are associated with statistically insignificant clinical outcomes, complicated mortality/morbidity data reports, and unconfirmed clinical effects which prohibited the trustful use of those drugs.\textsuperscript{33,34}
contrast, the new drug discovery approach is more complicated and time-consuming. However, it has the highest potential to find new pharmaceuticals which have unique advantageous properties for unique viral pandemic events.25

Biomaterials can endorse the fight against COVID-19 by enhancing immunomodulation and anti-inflammatory effects. Monoclonal antibodies can cross-react with SARS-CoV-2, block the viral attachment by disrupting the receptor-binding interface, and inactivate the virus by binding to S proteins.35,36 Tocilizumab (monoclonal antibody against interleukin (IL)-6), sarilumab (IL-6 receptor antagonist), HCQ, and CQ (blockers of pro-inflammatory cytokines) can be used as immunomodulators to counteract the systemic hyperinflammation.37–39 Biologicals are the foremost approaches in COVID-19 management. Convalescent plasma therapy (CPT) can neutralize SARS-CoV-2 in newly infected patients.40 Different inactivated and recombinant vaccines are now being developed from viral DNA fragments and they are being evaluated in different phases of many clinical trials.41

Scientists are still searching for the most appropriate, efficient, and effective diagnostic, therapeutic, and preventive strategies, including the use of new nano-based technologies. Nanotechnology-based research and development now appears to be essential to end the pandemic effectively and shortly.24 Nano-based detection with nanowire biosensor chips, graphene derivatives, and other types of nanostructures have been developed.9 Nano-based systems are effective for inhibiting pathogens and minimizing drug resistance profiles.42 Carbon nanotubes that demonstrated a noble nanocarrier property and enhanced drug release towards target cells in cancer therapy can be potential therapeutic alternatives against SARS-COV-2.43,44 Currently, many pharmaceutical research and manufacturing companies are turning to the use of nanotechnology for vaccine and drug development. Nanoparticles (NPs) are being increasingly investigated and used as new anti-SARS-CoV agents, vaccine carriers or adjuvants, and nanoscale biorecognition elements with a promising indication of nanomedicine as a potentially suitable option to end the fight against this pandemic.34,45

**Nanostructure-based COVID-19 Management**

Nanostructured material is a type of material with at least one nanometric dimension (usually less than 100 nm). They can be organic, inorganic, biomaterial-based, and carbon-based as shown in Figure 2. Their physicochemical properties such as, chemical reactivity, size-dependent transport, biocompatibility, and reduced toxicity attracted scientists in many fields. Medicine is one such fields with rising attention in applying nanotechnology.42 Nanostructure-based delivery systems demonstrated improved specificity and bioavailability over the traditional system. Much of the added value is related to NP
physicochemical properties which include controllable size, great surface area to mass ratio, and easily functionalizable structure. They can stabilize the drug in the systemic circulation for targeted, controlled, and sustained delivery, which, as a result, can increase the therapeutic advantage.\(^4^7\) Multiple targeting, in vivo imaging, and combined drug delivery are also their potential advantages.\(^4^8\) All these principles can be applied to fighting the COVID-19 pandemic.

**Why Nanostructure-based COVID-19 Management?**

As the pandemic continues to cause an enormous global crisis, there is still an unmet need to discern a favorable, safe, and typically effective approach for diagnosis, treatment, vaccination, and prevention to prohibit super-spreading of the virus and a mortality crisis.\(^4^9\) Diverse nanotechnological strategies have shown a promising capacity to address many of those unmet needs in the fight against the pandemic as stated in the next sections.

**Challenges in Biosafety**

COVID-19 exposed the world for too many discrepancies including an absence of effective vaccines and therapeutics, lack of rapid or real-time detection methods, shortage of protective equipment, and limitation in accessibility of support for infected patients. These biosafety problems arise mainly from limited research and considerations in materials science. A variety of nanostructured materials, such as polymers, inorganic-organic frameworks, biomaterials, graphene derivatives, and carbon nanotubes are radically transforming the way of countering biosafety challenges.\(^5^0\)

**Detection Time, Accuracy and Sensitivity**

Time-consuming detection processes like quantitative real-time PCR can be eradicated by applying NP-mediated sensing alternatives which can provide a rapid diagnosis.\(^5^1\) Limitations in antibody tests like technical production and identification problems, lack of suitability, and false positive or negative findings are reported from the conventional tests. Early stage detection, no or minimized contamination, and protected risk of error are also questions to be answered with more appropriate advances of testing.\(^5^2\)

**The Gap Between Diagnostics and Therapy**

Recently, the application of NPs has emerged as groundbreaking in the medical field that allows accurate diagnosis and specific treatment of a disease at once (theranostic approach). Nanotheranostics involve virus detection and simultaneous neutralization by using nanodrugs that target diagnostics and therapy.\(^5^3\) This approach helps to fill the existing gap between diagnostics and therapy. It has been widely demonstrated in cancer chemotherapeutic investigations and there have been substantial struggles to extend this advantage to other areas of medicine including infectious diseases.\(^5^4\)

**Unsupported Benefits of Repurposed Drugs**

Even though drug repurposing is a time-saving approach, the benefits of the repurposed drugs could not be fully supported with clinical outcomes and respective authorities. Unsatisfactory results from CQ and CQ, hepatotoxicity of remdesivir, unestablished harm or benefits of ACEIs, challenging safety/efficacy issues from the non-specific mechanism of CPT, and safety concerns on corticosteroid use were reported. Application of nanostructures to the repurposed drugs can help develop efficient therapeutic strategies with minimal safety/efficacy concerns.\(^5^2\)

**Targeting and Controlling Release**

SARS-CoV-2 mainly affects the respiratory tract, especially the lungs, with expanded effects on other organs such as the gut, kidney, and vasculatures.\(^5^5\) Therefore, the lungs are the most important organ for COVID-19 drug delivery. Targeting such sites and controlling drug release at target organs with conventional approaches is very difficult. Advances in inhalable NPs overwhelm such disadvantages, such as side effects from high serum drug concentrations and target inaccessibility. Nanotechnology-based intranasal drug delivery systems can overcome various limitations of mucosal administration.\(^3^4\) More accurate and controlled crossing of the blood–brain barrier (BBB) can be achieved with nanobiomaterials that can improve cell retention, survival, differentiation, and integration inside the CNS.\(^5^6\) Nanodelivery through the nasal cavity is not only simple and inexpensive, but also noninvasive and rapidly absorptive.\(^5^7\) In addition, biocompatible nanomaterials such as boron nitride oxide nanosheets can improve the adsorption of drugs towards different parts of the viral protein; help the drug diffuse rapidly to the viral protein, and improve drug–virus interaction.\(^3^1\)

**Vaccine Effectiveness, Stability and Release**

Conventional vaccines have limited efficacy against novel pathogens due to their low blood stability as well as short and insufficient immune response that drives the need for
higher doses. In addition, they are associated with short half-life, poor immunogenicity, non-targeting, slow absorption, and high storage and delivery requirements. Nanobiomaterials can be used as adjuvants for vaccines with special characteristics of reduced systemic toxicity and better targeting. There are also associated challenging issues, such as high pathogenic variety, high viral mutation rate, and complex host-related failures, resulting in an inappropriate immune response. Nanovaccinology comes with an effective alternative that results in strong immunostimulatory effects, manageable size and surface properties, controllable drug release, and strong stimulation of humoral and cellular responses.

**Surface Disinfection Efficacy and Duration**

Disinfecting all surfaces and objects all the time is practically impossible, and one cannot be sure that the surface/object will not be contaminated again. Surface coating with nanomaterials that can inactivate the viral cell can be an advantageous advance for designing contamination-free equipment. Self-disinfecting surfaces can be prepared using nanomaterials with intrinsic antipathogenic effects. Surfaces with inherent virucidity, antimicrobial releasing self-sanitizing surfaces, and surface topologies with viral self-deactivation are some among the novel surface nanodisinfecting applications.

**Protective Efficiency, Safety and Duration**

As PPE plays the greatest role in combating the pandemic, it is equally essential to critically consider their sufficient supply, storage, waste management, and appropriate use. Actually, the current trend of applying the PPE could not eliminate the viral transmission as expected which necessitates a modification for their production and use. Environmental safety and waste management related to PPE is another complicated issue during the pandemic season as it becomes burdensome, resulting in a health compromising situation including carcinogenic health impacts. Therefore, it is recommended to use available alternative technologies for the production of biomedical equipment and treatment of COVID-19-related waste. Moreover, disposable PPE becomes one of the major factors in environmental pollution and source of biohazards creating critical environmental issues globally. If this remains unsolved, it may be a long-term threat to human and aquatic organisms. This can be potential long-term physical, physiological, and pathophysiological effects. Nanostructures can improve PPE efficacy and safety by providing reusable, self-cleaning, high efficiency, and effective products with antimicrobial and antiviral properties. Intrinsic antiviral NPs, nanofibers and NP-coatings that can provide super-hydrophobicity, water-repelling, synergistic, and self-cleaning effects are some of the applicable nanostructures. Nanotechnology can generally convey advanced therapeutic, diagnostic, and prevention options than conventional as summarized in Table 1.

**Nanostructure-based Approaches in COVID-19 Management**

Nanotechnology has huge potential for fighting the COVID-19 pandemic, since it enables targeted drug or vaccine delivery to physiologically inaccessible targets; increases drug loading and transport, and provides intrinsic/synergistic virucidal activity. It can also possess simple, fast, and cost-effective alternative disinfection methods; provide targeted pulmonary drug delivery, and offer ways for designing better immunomodulating materials. It can generally contribute to antimicrobial, anti-inflammatory, diagnostic, theranostic, therapeutic, biosensing, preventive/proective equipments, immunomodulation, and vaccination approaches against the pandemic. The different application of nanotechnology during the fight against the COVID-19 pandemic is summarized in Figure 3. NPs possess a comparable size and structure with the virus as they both act at the same nanoscale, that makes their use paramount and suitable for the development of vaccine and immune engineering. This also allows the NPs to bind, encapsulate and passivate the virus, permitting easily detection, treatment, and prevention. Generally, nanomaterials can induce an external stimulus that is responsible for killing the virus or directly interact with the virus with their surface properties to act as antiviral agents. Nanodiagnostics, surveillance and monitoring, nanotherapeutics, and nanovaccination can provide the next generation of fighting approaches against the outbreak.

**Nanodiagnostic Applications**

Nanotechnology, in SARS-CoV-2 detection, can be applied in the form of nucleic acid testing (amplification of nucleic acid with NPs under isothermal conditions); point-of-care testing (POCT) (diagnose infected individuals, without the need of sending patient samples to laboratories via simple color changes after applying nanostructures); electrochemical sensors (high sensitivity and
possibility of miniaturization with metallic NPs); chiral biosensors (NPs conjugated with coronavirus specific antibodies), etc.\textsuperscript{80,81}

### Point-of-care Diagnostics (POCD)

Since the infection is easily transmissible from human to human, the diagnostics should better be at POC without the need for experienced labor, complex time-taking procedures, and sophisticated laboratories.\textsuperscript{82} POCD provides a diagnostic outcome with improved laboratory quality in real-time, within minutes and not hours. Nanotechnology can further advance the POCD approach by adding nanosensor technology, microfluidic channel devices, bio-analytical platforms, assay formats, lab-on-a-chip technologies, and complementary advances.\textsuperscript{83} NPs can assist the immuno-chromatographic test (ICT), also known as lateral flow immunoassays (LFIA), for detecting the antigens or antibodies rapidly with a POC. The advantages of this system includes; detection of both symptomatic and asymptomatic patients, not requiring trained staff, triage of patients avoiding further spreading, diagnosis when laboratory facilities are unavailable, easy of use, small sample amount, and timely detection in less than 20 min.\textsuperscript{84,85}

### Rapid Diagnostic Kits

The principle of rapid diagnostic kits works by direct isolation of RNA from a patient sample. Metallic and magnetic NPs, such as gold and iron oxide NPs, have been widely investigated so far and demonstrated improved testing accuracy, specificity, time, and reliability.\textsuperscript{86,87} Gold NPs coupled to complementary DNA sequences demonstrated a color change from red to blue indicating the formation of a tertiary complex with the viral antigen after the immobilization and agglomeration of the NPs.\textsuperscript{88} Metal oxide NPs in complement with a silicon-on-insulator nanowire sensor showed a rapid and

---

### Table 1: Comparison Between the Conventional and Nanobased COVID-19 Management Approaches

|                        | Conventional Approach                                                                 | Nanotechnology-based Approach                                                                 |
|------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| **Diagnosis**          | - Lengthy time of detection                                                            | - Early stage detection                                                                      |
|                        | - Limitations in antibody tests like technical production and identification problems | - No or minimized contamination                                                              |
|                        | - Lack of suitability                                                                  | - Protected error risk                                                                       |
|                        | - False positive or negative findings                                                  | - Sensitivity                                                                               |
|                        |                                                                                        | - Possibility of miniaturization with metallic NPs                                          |
|                        |                                                                                        | - NPs conjugated with coronavirus specific antibodies                                        |
| **Treatment**          | - Absence of effective therapeutics                                                    | - Stabilized in the systemic circulation                                                    |
|                        | - Low surface area to mass ratio                                                       | - Targeted, controlled and sustained delivery                                                |
|                        | - Chemical reactivity/instability                                                      | - Controllable size and size-dependent transport, biocompatibility                           |
|                        | - Side effects from high serum and non target concentrations                           | - Reduced toxicity                                                                           |
|                        | - Inaccessibility of the target by the drug                                            | - Theranostic approach                                                                       |
|                        |                                                                                        | - Non-invasive administration like inhalations                                               |
| **Vaccines**           | - Low blood stability, slow absorption and short half-life                              | - Multiple targeting                                                                        |
|                        | - Insufficient immune response                                                         | - Strong immuno stimulatory effects                                                          |
|                        | - Higher doses – risk for side effects                                                | - Manageable size and surface properties                                                      |
|                        | - Poor immunogenicity, non targeting, slow absorption                                  | - Reduced adverse effects                                                                    |
|                        | - High storage and delivery requirements                                               | - Controllable drug release                                                                  |
| **Personal protective Equipment (PPE)** | - Shortage of supplies                                                                 | - Reusable and improved bio-safety                                                           |
|                        | - Low filtration efficiency                                                            | - Self-cleaning, high efficiency and effective disinfectants with antimicrobial and antiviral properties |
|                        | - Single-use (use-and-throw) – economic, eco-safety and waste management problems     | - Designing contamination-free equipment                                                      |
|                        | - Breathing pressure and heat dissipation                                              | - Adding inherent virucidity to surfaces                                                     |
|                        | - Ineffective disinfection and sanitizing                                              | - Antimicrobial releasing self-sanitizing and surface topologies with viral self-deactivation |

---

\(5719\)
very sensitive SARS-CoV-2 antibody detection in 5–15 min. Magnetic NPs (MNPs), especially iron oxide NPs, can easily separate the viral RNA from sample solution with their high magnetic efficiency to prepare analyte preconcentration, signal amplification, and biosensing. Silica-coated super-paramagnetic NPs improved the selectivity of the detection during PCR-based assays by forming magnetic-conjugated DNA complexes, which then can be magnetically separated and amplified through PCR. Field-effect transistors based on graphene demonstrated the most rapid SARS-CoV-2 detection in less than a minute. The precision of PCR can also be enhanced by using graphene NPs.

Nanostructured Biosensors

NP-based biosensors can minimize the conventional time-consuming steps, like in the case of quantitative real-time PCR, and provide pronounced advances in rapid diagnosis. The SARS-CoV-2 biosensor using thiol-modified antisense oligonucleotide-capped glyconanoparticles can diagnose positive COVID-19 cases visible with the naked eye through color change within 10 min. The glyconanoparticle platform with a lateral flow diagnostic device demonstrated a low-cost and rapid detection in less than 30 min. Nanobiosensors integrated with bio-informatics can provide individualized approaches by correlating infection progression with sociodemographic parameters like race, gender, age, and region that can further optimize targeted testing, tracing of asymptomatic patients (carries), and detection of discharged patients for re-infection. Different nanostructured biosensor applications are presented in Figure 4.

Nanomaterial-based Detection Using Smartphone

Nanopapers and nanochannels are nanomaterial-based sensors that advance the lateral-flow devices to detect at observation level with smartphones or the naked eye. They offer cost-efficient options for viral detection. Battery-operated and smartphone camera-based amplifications with inorganic quantum dots are coming to be the next generations for SARS-CoV-2 detection. Smartphone-based sensing systems are semi-automated, personally accessible, user-friendly, and applicable with less training. The sensing system is connected to the smartphones; NPs are employed peripherally; analysis is conducted by the sensing system, and finally, the smartphone itself will interpret the results. It is individualized and takes less time than PCR. Some examples of nanomaterials investigated for diagnosis of COVID-19 are listed in Table 2.

Figure 3 Potential nanotechnology applications for combating SARS-COV-2. Copied from Rai M, Bonde S, Yadav A, et al. Nanotechnology as a shield against COVID-19: Current advancement and limitations. Viruses. 2021;13:1224. doi: 10.3390/v13071224.
Nanotheranostic Applications

In recent times, nanostructured systems have brought a groundbreaking advance in medicine, in which accurate detection and specific therapeutics of disease conditions can be conducted at once (theranostic approach). Theranostics can provide detection and neutralize the viruses using NP-based approaches which will possess a great prospective in controlling the COVID-19 pandemic as NPs can amplify the detection, inhibit viral replication, and disrupt all possible virus–host interactions. Thus, nanotheranostics can fill the existing gap between diagnostics and therapy. Nanotheranostics is a new field in medicine that combines NP-based targeted therapy based on diagnostic tools to efficiently and selectively deliver drugs, vaccines, and biologicals to the target sites of infection. It has the ability to monitor infectious sides, deliver treatments, and assess therapeutic responses with noninvasive imaging approaches.

Several approaches are being investigated for smart nanotheranostic application by combining bioactive targeting and nanodiagnostics to deliver therapeutics with concomitant real-time response monitoring; minimized probability of over- or under-dosing, and noninvasive imaging techniques. Nuclear imaging with radiolabeled nanomaterials, inorganic NPs, organic NPs like polymers, carbon-based nanomaterials, and vesicular nanostructures like nanosomes, are some of the multifunctional nanotheranostics.

Nanotherapeutic Applications

Therapeutic nanostructures can block viral entry, inhibit its replication, deliver drugs as nanocarriers into the target organ,
and assist vaccine formulation and delivery as summarized in Figure 5. In general, they target the SARS-CoV-2 entry and life-cycle with a special emphasis on the S protein as it is the most important factor for viral entry and host cell interactions. Nanomodification of repurposed drugs like dexamethasone and CQ demonstrated promising anti-edema, antifibrotic, and anti-inflammatory mechanism predicting NP-uptake in cells. Nanostructure-based drug delivery can

| S No. | Nano-Formulation                                                                 | Features of the Nanoformulation                                                                 | Reported Benefits of Nanoforms                                                                 | Reference |
|-------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------|
| 1.    | Dual-functional plasmonic photothermal biosensor                                 | The two-dimensional gold nanoislands (AuNIs) functionalized with complementary DNA receptors     | • Sensitive detection of the selected sequences  
• Precise detection of the specific target in a multi-gene mixture | 88        |
| 2.    | Graphene-based field-effect transistor biosensing devices                        | Graphene NP-based sensors coated with specific antibodies against SARS-CoV-2 S protein         | • Specific targeting of S protein  
• Low concentration detection  
• Highly sensitive, rapid and on-site detection | 92        |
| 3.    | COVID-19 rapid test cassette (SureScreen Diagnostics Ltd)                        | Au NPs embedded in the nitrocellulose test strip integrated with lateral flow devices            | • High sensitivity and reliability of visual detection  
• Used in point-of-care (on-site) detection  
• Significant time and cost saving  
• Detection even in mild or asymptomatic cases  
• Easy to use and read | 99        |
| 4.    | Smart Detect SARS-CoV-2 rRT-PCR kit                                             | Nanobiomaterial of oligonucleotide primers and probes labeled with fluorescent reporter dyes and quenchers | • Single-well detection of 3 different targets  
• Endogeneous control informs effectiveness of procedures/overall specimen quality | 100       |
| 5.    | Chiral zirconium Quantum dots                                                    | Nanocrystals for optical detection synthesized using L()-ascorbic acid                            | • Greater sensitivity than conventional ELISA methods                                           | 101       |
| 6.    | CRISPR-based DETECTR lateral flow assay                                         | Using synthetic, in vitro transcribed SARS-CoV-2 RNA gene targets in nuclease-free water        | • Rapid (~30 min), low-cost, and accurate  
• 90% sensitive and 100% specific for detection  
• No cross-reactivity for related coronavirus strains | 102       |
| 7.    | Lanthanide-doped NP-based lateral flow immunoassay                               | Self-assembled lanthanide-doped polysterene NPs dispersed by recombinant nucleocapsid phosphoprotein | • Rapid and sensitive lateral flow immunoassay  
• Useful for progression monitoring and evaluating  
• Patients’ response to treatment | 103       |
| 8.    | Magnetic NPs for RNA extraction and isolation                                    | Synthesis of polymer coated amino-magnetic NPs (Poly-NH2-MNP)                                    | • Rapid detection  
• Allows processing of ~10,000 tests per day  
• Guaranteeing to reach a wide range of population | 104       |

Abbreviations: ELISA, enzyme-linked immunosorbent assay; MNP, magnetic nanoparticle; NP, nanoparticle; rRT-PCR, real-time reverse transcription polymerase chain reaction.
be either passive (drugs loaded and transported with nanocarriers) or active self-delivery (drug molecules themselves are nanosized). Since SARS-CoV-2 initiates its infection on the nasal cavity, nasal cavity-based nanodelivery is very important and promising for targeted COVID-19 management with simple, inexpensive, noninvasive, and rapidly absorbable approach. These systems are believed to improve therapeutic efficacy without compromising safety. Several nanodeliveries with enhanced antiviral activities against SARS-CoV-2 have been investigated, reported, and it is claimed that they can synergize the global fight against the pandemic. Some examples from these investigations are described in Table 3.

### Organic and Inorganic Nanoparticles

Organic NPs such as liposomes, dendrimers, micelles, and polymers can have nanovirucidal effects and inactivate viral cells including SARS-CoV-2. They can be formed in combination with each other or with inorganic NPs to form hybrid nanosystems based on specific use at the targeted site. Inhalable organic and inorganic NPs (Figure 6) can be used for targeting the lung to overcome side effects from high serum concentrations of conventional administrations. Nano-drug co-deliveries can reduce particle size-dependent safety issues in lung and respiratory systems. Corticosteroid-loaded PLGA NPs, solid lipid NPs, N,N-dimethylaminoethyl methacrylate, and butyl methacrylate monomers can be used for effective and safe pulmonary delivery to prevent systemic immunosuppression effects of the drugs. Inorganic NPs like transition metal NPs (Ag, Cu, Zn), metal oxides (Fe₂O₃, TiO₂, ZnO₂,), and carbon-based NPs have intrinsic antipathogenic effects by interfering one or more viral life-cycle stages. Mesoporous silica NPs provide drug co-delivery which can further be functionalized with ligands for active targeting of the viral cell. AgNPs are better drug carriers for nucleic acid-based delivery with increased stability, protection from degradation, and controlled intracellular delivery. AuNPs, carbon-based NPs, polymeric NPs, and vesicular nanocarriers have the potential...
to induce cytokine and antibody responses which are dependent on their size, shape, and surface chemistry. By modifying these properties with respect to different targeting moieties, they can be promising strategies for targeted antigen delivery.127,128

### Nanobiomaterials

Biomaterials are substances that are either formed by living organisms or extremely compatible by their nature. Novel biomaterials at their nanoscale level possess precise and effective drug delivery functions.129,130 Biomaterials are

| S. No | Nanoformulation | Features of the Nanoformulation | Reported Benefits of Nanoforms |
|-------|-----------------|---------------------------------|--------------------------------|
| 1.    | Dexamethasone with biomimetic NPs | Encapsulating dexamethasone with leukocyte-derived nanovesicles (leukosomes) | - A significant survival advantage  
- An improved immune response resolution  
- Enhanced therapeutic activity of dexamethasone |
| 2.    | Inhalable liposomal HCQ | HCQ encapsulated in liposomes for inhalational administration preparation | - Improved pharmacokinetics  
- Efficient aerosolized delivery  
- Targeted antiviral levels with lower effective dose and less dosing frequency  
- A sustained release  
- Reduced systemic exposure |
| 3.    | CQ/HCQ-coated metallic NPs | Adsorption of HCQ/CQ on Ag, Au, AgAu and Pt NPs. | - Decreased side effects  
- Low toxicity  
- Improved antiviral activity |
| 4.    | Liposomal lactoferrin | Lactoferrin (Lf), a multifunctional glycoprotein, loaded in liposomes | - Noninvasive oral and intra-nasal use  
- Enhanced antiviral activity  
- Under Phase 2 clinical trial |
| 5.    | Nanospores | Cellular nanospores produced from human cell membranes, attached with macrophages | - Mimicked ACE-2, inhibit viral entry and attachment  
- SARS-CoV-2 is neutralized and unable to infect  
- Dose-dependent inhibition of the viral infectivity |
| 6.    | Peptide functionalized AuNPs | The AuNP functionalized by new peptide | - Forms the most stable complex with RBD.  
- A great potential to inhibit the RBD of SARS-CoV-2  
- Good antiviral agents against COVID-19 |
| 7.    | Membrane-based ACE2-Rich NPs | Nanoparticles made from the membranes of ACE2-rich cells | ✓ Prevented viral binding to host cells via competitive inhibition  
✓ Effective anti-SARS-CoV-2  
✓ Easy to produce |
| 8.    | Liposomal remdesivir | Aerosolized nanoliposomal carrier of remdesivir | - Direct administration into the lungs.  
- Drastically minimized side effects and  
- enhanced efficacy  
- Easy self-administration at home.  
- An effective alternative for COVID-19 treatment. |

Abbreviations: ACE2, angiotensin converting enzyme-2; CQ, chloroquine; HCQ, hydrochloroquine; NP, nanoparticle; RBD, receptor-binding domain.
reported for reducing mortality in COVID-19 patients. Investigations are being made with remarkable efforts to apply them in controlled delivery, for minimizing systemic administration complications, and alleviating disease severity.\textsuperscript{131} Bioengineered platforms of airway models are used to elucidate the pathophysiological processes of COVID-19 which is a rate-limiting step for management procedures and recommendations.\textsuperscript{132} Their biologic and physicochemical properties can be operated as to the different needs for therapeutic applications including the current pandemic.\textsuperscript{133} Tissue engineering and regenerative medicine are now providing promising solutions to viral outbreaks in diagnostics, treatment, vaccination, and surface disinfection which can be implied for their application toward COVID-19.\textsuperscript{134} Organoids (clusters of organ-specific cells) were formed as effective models for COVID-19 viral examination. In addition, microfluidic organ-on-chip (OoC) systems have recapitulated host physiology, viral pathology, and therapeutic responses with high accuracy.\textsuperscript{135,136} Biomaterials have the potential to modulate the immune response, advance drug repurposing, and prevent or treat complications of COVID-19.\textsuperscript{137,138} Moreover, the nano-forms of biomaterials can improve quality of life by reducing the adverse effects of conventional therapeutics. Therefore, highly efficient, reliable, compatible, and recyclable biomaterial-based applications can support the fight against the current pandemic.\textsuperscript{46} Nanobiomaterial therapeutics can be used to deliver cargo directly to the respiratory targets (lungs) to avoid nontarget effects as they can be synthesized according to the ideal size range and controllable release for cellular targeting.\textsuperscript{139} Furthermore, many nanobiomaterials have intrinsic low cytotoxicity and high biocompatibility which are the currently needed essential attributes for COVID-19
management. Nanobiomaterials in conjunction with Ag and mesoporous silica NPs could be used for the delivery of anti-inflammatory cytokines to counter the inflammation associated with COVID-19.\textsuperscript{138}

Nanobiomaterial forms, such as gum-based hydrogels, nanogels, multilayered polyelectrolyte films, DNA aptamers, and nanocarriers like nanocapsules, nanospheres, and polymers demonstrated a potential effect that can add to the fight against COVID-19.\textsuperscript{22,126} Biomaterials in the form of nanoemulsions, nanodecoys, virus-like NPs (VLNPs) and self-assembly systems are being investigated and suggested for use against COVID-19. Nanoemulsions can easily transcytose lipophilic antigens across the intestinal cells. In addition, they can be synthesized with low cost and easy procedures; require easy storage conditions; demonstrate increased absorption rate and bioavailability; possess thermodynamic stability; provide solubility of lipophilic drugs, and improve the antiviral activity of the drug.\textsuperscript{140} Nanodecoys are cell membrane nanovesicles formulated to display high levels of ACE2 and cytokine receptors with the aim of competing for viral and cytokine binding. They can significantly inhibit SARS-CoV-2 replication and neutralize inflammatory cytokines.\textsuperscript{141} VLNPs are sphere-shaped NPs formed from several nanosized molecules and the self-assembly of viral proteins. They do not have genetic material content but structurally mimic the real virus enabling them to highly attract antigen-presenting cells and stimulate the immune response.\textsuperscript{105} Self-assembling NPs are excellent in carrying the drug, easily crossing the cell membranes, releasing drugs in a controllable manner at the target site, and synergistically activating the immune system.\textsuperscript{121}

Nanobodies are other types of nanobiomaterials that can identify the pathogens, envelop the virus, and neutralize its functions. Hence, they can be diagnostic or therapeutic tools against the SARS-CoV-2 virus.\textsuperscript{79} Researchers have isolated high stability nanobodies that can bind to spike protein of SARS-CoV-2, detect at an atomic level, and block the virus very specifically.\textsuperscript{142} The world’s first humanized antibody against the SARS-CoV-2 inflammatory storm was discovered which can specifically damage the viral critical stage in the lungs. With little modification by using drug-loaded NPs, it can provide easy access for air sacs and blood vessels for free delivery of oxygen and blood.\textsuperscript{143} Cellular nanosponges made of the human plasma membrane epithelial type II cells or macrophages are reported as an effective countermeasure to SARS-CoV-2 since they display the same protein receptors required by SARS-CoV-2 for cellular entry. Therefore, they will neutralize and mutate SARS-CoV-2 making it unable to infect.\textsuperscript{117,136}

Nanofibrous hybrids are active antiviral and antibacterial membranes that are formed embedded with AgNPs by an electrospinning process. They have subsequent screening with potential antiviral activities against different viruses, including SARS-Cov-2. They can also be applied in PPE and surface disinfection developments.\textsuperscript{144} Eco-friendly non-spherical nanocellulose nanofiber is synthesized which is a sustainable, nontoxic, low-cost, and biocompatible carrier with antimicrobial effects.\textsuperscript{145} Antibodies conjugated to biomaterial-based NP surfaces allow efficient and effective inflammatory marker removal caused by the cytokine storm. Chitosan, hyaluronic acid, PLGA, and mesoporous silica NPs can be used for surface conjugation to reduce the burden of SARS-CoV-2 cytokine storms. Ligand-based nanoparticle biomaterials possess sequestration of cytokines and active-targeting for viral inactivation. The immune modulation effect of these systems can be assisted by co-delivery of anti-inflammatory drugs.\textsuperscript{138}

**Nanophytomedicines**

Nano-sized herbal medicines have been developed as nanophytomedicines based on their unique nature. Various nanotechnology-based systems such as polymeric NPs, solid lipid NPs, magnetic NPs, metal and inorganic NPs, nanospheres, nanocapsules, quantum dots, nanoemulsions, polymeric micelles, liposomes, and dendrimers have been tried for the successful delivery of natural products from traditional medicine. This brings potential herbal drug-loaded pharmaceutical carriers for alternative and complementary medicine to the modern system which can push the fight against many chronic and pandemic global issues like COVID-19 one step forward.\textsuperscript{146,147} Since the occurrence of COVID-19, diverse traditional medicines have been used alone or in combination with the conventional management systems. These herbal extracts may possess anti-SARS-CoV-2 actions by disrupting the viral life-cycle that can be a promising preventive and therapeutic alternative to the pandemic.\textsuperscript{148} In addition, their favorable oral stability and ease of scaling up make them ideal contenders for prophylactic and prevention strategies including vaccine development.\textsuperscript{149} Reports indicated that Chinese, Indonesian, and Nepalese people increased the use of medicinal plants during the COVID-19 pandemic claiming that they can prevent or cure the disease and it is believed to have shown good results in
fighting SARS-CoV-2 empirically.\textsuperscript{45,150–152} Adeleye et al, identified 15 potential ethnomedicinal herbs from different African countries for the discovery and development of therapeutic agents for COVID-19 applications.\textsuperscript{153} Phytotherapeutics has been recognized for its better therapeutics with fewer adverse effects than modern medicines. However, it needs a novel scientific approach for modified, sustained, and controlled delivery to enhance patient compliance and avoid repeated administrations. This can be achieved by designing nanostructured delivery systems and integrating them with nanocarrier approaches that can enhance its therapeutic activity while overcoming associated problems, such as bulk dosing and lower bioavailability.\textsuperscript{144}

The sole combination between traditional medicine and nanomedicine will accompany a new era of affordable, safe, and effective medicinal systems that can be very supportive for a pandemic crisis like COVID-19.\textsuperscript{154} Plant metabolites and body parts of microorganisms can be delivered by spherical NPs as a potential strategy for antiviral therapies.\textsuperscript{145} Glycyrrhizic acid, a common ingredient in the Chinese herb licorice, has a known anti-SARS-CoV effect, but its application is limited due to cytotoxicity, poor water and bio-fluid solubility, and low bioavailability. Synthesizing highly biocompatible glycyrrhizic acid NPs demonstrated a significantly enhanced antiviral and anti-inflammatory effects in vitro and in vivo.\textsuperscript{152} A typical Indonesian natural product administration culture, called jamu, is commonly practiced to relieve pain and inflammation from acute and chronic disorders. The efficacy and the value of jamu have been improved using various nanotechnology approaches such as nanosuspension, nanoemulsion, nanoencapsulation, and nanofiber fabrication.\textsuperscript{151} Researchers at Alfaisal University combined AgNPs with a black tea extract (theaflavin) and attained a potent viral replication inhibition effect that can assist in the fight against COVID-19 by slowing the viral reproduction rate in a host and reducing the severity of symptoms.\textsuperscript{155}

**Nanostructures for Postinfection Complications**

Nanostructures can also be used in the prevention of major organ complications, co-infections and postrecovery syndromes of COVID-19 infected patients. Antiviral nanobiomaterials, in the form of external vesicles, exosomes and artificial nerve conduits can cross the BBB; promote synaptic plasticity; modulate immunity for poststroke pain and inflammation; facilitate neural regeneration, and treat neuropathies associated with COVID-19.\textsuperscript{56} Nanotargeting of cytokine receptors using lipid nanoemulsions demonstrated a promising application for minimizing dementia and brain inflammatory neurodegeneration which is a risk factor for Alzheimer’s disease.\textsuperscript{156,157} The alarming rate of antimicrobial resistance with the upsetting emergence of new pathogens like SARS-CoV-2 will challenge the therapeutic approaches to many infectious diseases, which as a result, demand an accurate, fast, sensitive, specific, simple, and inexpensive diagnostics and therapeutics strategy.\textsuperscript{158} Ag, Au, iron oxide, and titanium dioxide can be valuable NPs to combat secondary microbial infections and multidrug resistance in critically ill patients during COVID-19 infection which is known as “a silent risk”.\textsuperscript{42,159} Furthermore, nanotechnology can help to address COVID-19-associated pneumonia by delivering anti-inflammatory nanodrugs and antioxidants; providing inhalation methods; and utilizing oxygen-generation nanomaterials.\textsuperscript{160} Niclosamide-loaded albumin NPs, chitosan nanocarriers, biopolymer-derived nanocarriers, and lipid NPs demonstrated a highly viral entry inhibitory effect against SARS-CoV-2 in vitro and showed an extended circulating drug exposure in vivo, with a new, cheap, and scalable preparation process.\textsuperscript{161} In sum, all these nanotherapeutic strategies can provide timely solutions for combating the pandemic and open the door for future explorations.

**Nanovaccination**

Vaccines appear to be the preeminent solution in combating the pandemic even though their development, clinical trial processing, approval, and scale-up are time-consuming. But, investigations are being undertaken as quickly as possible. SARS-CoV-2 vaccine development is the most astonishing one in history by getting into clinical trial phases within only three-to-six months which makes it the fastest of all the epidemics and pandemics.\textsuperscript{162} The application of nanomaterials in vaccine development and delivery has led to the birth of the concept of “nanovaccinology”. NP-based vaccines with organic, inorganic, hollow polymeric, and biologic NPs possess potential benefits such as high payloads, tailorable size and surface properties, controllable and targeted release kinetics, improved stability, easy antigen uptake, and strong response induction.\textsuperscript{60,163} Nanobiomaterials can be vaccine adjuvants to enhance vaccine efficacy due to their lower systemic toxicity, stronger targeting, higher specific surface area, and lower immune titer.\textsuperscript{58,59}
Subunit vaccines with NPs, such as virus-like proteins (VLPs) and protein NPs, are under active consideration in development processing. The receptor-binding domain (RBD)-based SARS-CoV vaccines are also considered as effective strategies. VLPs are desirable NPs that stand out to cells that produce antigens; easily detect them, and stimulate an immune response. They can better be delivered through the lymph and capillaries, easily entering into the cell; reducing the systemic inflammatory response; increasing vaccine immunogenicity and efficacy; improving patient safety; and boosting the immune system. Nucleic acid-based vaccines demonstrated an enhanced delivery efficacy and stability when they are applied with cationic liposomes, dendrimers, and solid lipid NPs. Vaccines formulated with exosomal S protein of SARS-CoV resulted in induced and accelerated antibody neutralizing effect.

NP-based inhalational vaccines provide high mucosal immunity in the lungs which are the main targets in respiratory infections like SARS-CoV-2. Intranasal vaccine delivery offers admirable safety, better convenience, both systemic and local immune response for controlling respiratory infections like SARS-CoV-2. PLGA NPs functionalized with ACE2 receptor proteins from alveolar epithelial cells and macrophages can neutralize viral infectivity. Extracellular vesicles containing ACE2 as decoys and ACE2 mRNA packaged with lipid NPs achieved a critical host mimicry to distract the host-binding ability of SARS-CoV-2. Silica NPs coupled with polyethyleneimine showed easy trapping, protection, and delivery of DNA/RNA antigens into cells with potential adjuvant effect, great loading capacity, robust bonding, and enhanced cellular uptake. Quantum dots (QDs), with much smaller sizes than the known NPs, have also shown a promising utilization for COVID-19 vaccine designing. Lipid-based NPs (LNPs) opened the way forward to COVID-19 and they are now considered as the frontrunner in nanoscale vaccine development and delivery. They promised for the potential success of mRNA-LNP vaccines and, therefore, a long journey of optimizing LNPs for nucleic acid-based delivery has been passed. NP-based vaccine development is now on the way in various pharmaceutical companies and research institutes. Table 4 demonstrates some of the WHO-listed nanovaccines which are in clinical and preclinical phases.

Most NPs for use in nanovaccines are known to be biodegradable, biocompatible, and less toxic and, therefore, they can be safe and effective alternatives to the conventional vaccines. However, nanovaccine-related side effects and safety concerns still remain to be investigated.

Severe allergy-like reactions were reported from Pfizer and BioNTech novel vaccine products which is proposed to be due to nanopackaging compounds of the messenger RNA (mRNA). Polyethylene glycol (PEG) in vaccines may occasionally trigger anaphylaxis that causes a potentially life-threatening reaction with complicated respiratory and cardiovascular disorders. LNPs in the Pfizer/BioNTech and Moderna vaccines’ human trials demonstrated inflammation-like side effects such as pain, fever, swelling, and sleepiness. Oxidative stress, genotoxicity, hypercytokinemia, injection site inflammation, distribution, and persistency are also linked with nanovaccine toxicology. These side effects are probably associated with the antigen-NP, NP-antigen presenting cell, NP-biosystem, and adjuvant-NP interactions. In the case of a pandemic crisis like the current one, risk is weighed against potential benefit for any new advance.

**Nanopreventative Applications**

Nanomaterials can ultimately improve the COVID-19 prevention approaches by enhancing the surface disinfection, sanitization, and protective equipment efficiency and effectiveness as demonstrated by some investigation reports in Table 5. The use of nanomaterials in the production of PPE brings them new and improved properties in terms of resistance, efficacy, comfort and safety as summarized in Figure 7. The principles for the application of nanotechnology in COVID-19 prevention strategies are presented in the sections below.

**Nanotechnology-based Surface Disinfection**

Various chemical disinfectants are being applied widely in personal, household, and medical facilities for exhaustive sterilization during the pandemic. These include alcohols, phenol-based disinfectants, quaternary ammonium compounds, chlorine-releasing agents, iodophores, and high-level disinfectants like formaldehyde. However, it is practically impossible to sanitize surfaces all the time, and there is no guarantee for the surface not to be recontaminated. Investigation is underway for smart surface coatings with inherent virucidal materials and self-disinfecting abilities by the application of nanostructured techniques to surface disinfectants. These techniques include addition of intrinsic antiviral NPs, polymerization...
with intrinsically pathogen-resistant nanomaterials, metallic surface coatings, and nanotexturing.192

Various metal and metal oxide NPs such as AuNPs, AgNPs, ZnONPs, CuONPs, SiONPs, nanosized copper (I) iodide NPs (CuINPs), and quaternary ammonium cations commonly (QUATs) are capable of inactivating virus from surfaces.9 Metallic NP-based disinfectants have interesting features in terms of fabrication process and cost, safety and toxicity, life-span, antiviral activity, eco-friendliness, non-irritating, and nonfoaming properties to protect the pandemic viral transmission.19 They can be synthesized using the green synthesis approach from natural resources such as plant parts, insects, and animals. They provide an adsorbent property by their larger effective surface area, and a controlled release of the disinfectant molecules.193,194 They can be used for coating surfaces to oxidize and release ions with antimicrobial properties for disinfection. Controlled and sustained ion diffusion from metals like Cu modulates antiviral characteristics of surfaces.195 In addition; they are dermatologically safe and excellent in

| S. No | Novel Vaccine Platform | Features of the Nanoformulation | Developer/Organization | Status       |
|-------|------------------------|---------------------------------|------------------------|--------------|
| 1.    | Protein subunit        | SARS-CoV-2 rS/Matrix M1-adjuvant (Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) | Novavax | Clinical – Phase 3 |
| 2.    | DNA-based vaccine      | Covigenix VAX-001 – DNA vaccines + proteo-lipid vehicle (PLV) formulation | Entos Pharmaceuticals Inc. | Clinical – Phase 1 |
| 3.    | Protein subunit        | Recombinant Sars-CoV-2 spike protein, Aluminum adjuvanted (Nanocovax) | Nanogen Pharmaceutical Biotechnology | Clinical – Phase 1/2 |
| 4.    | Virus-like particle    | An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant. | VBI Vaccines Inc. | Clinical – Phase 1/2 |
| 5.    | RNA-based vaccine      | Self-replicating mRNA vaccine formulated as a lipid nanoparticle (LNP). | SENAI CIMATEC | Clinical – Phase 1 |
| 6.    | DNA-based vaccine      | Plasmid DNA, nanostructured RBD | National Institute of Chemistry, Slovenia | Preclinical |
| 7.    | Viral vector (non-replicating) | Lentiviral vector retro-VLP particles | Sorbonne University | Preclinical |
| 8.    | Protein subunit        | RBD protein delivered in mannose-conjugated chitosan NP | Ohio State University/Kazakh National Agrarian University | Preclinical |
| 9.    | Protein subunit        | S subunit intranasal liposomal formulation. | University of Virginia | Preclinical |
| 10.   | Protein subunit        | Recombinant protein, nanoparticles (based on S-protein and other epitopes) | Saint-Petersburg Scientific Research Institute of Vaccines and Serums | Preclinical |
| 11.   | RNA-based vaccine      | LNP-encapsulated mRNA cocktail encoding VLP | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | Preclinical |
| 12.   | RNA-based vaccine      | Liposome-encapsulated mRNA | BIOCAD | Preclinical |
| 13.   | RNA-based vaccine      | A self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the spike (S) protein | Zippius Vaccines and Ghent University | Preclinical |

Abbreviations: LNP, lipid nanoparticle; RBD, receptor-binding domain; VLP, virus-like particle.
Surfaces can be coated by nanopolymers in different ways. First, with a simple drop-casting method, a polymer solution will be dropped to coat the surfaces and then allowed to evaporate. In the second method, a dip coating technique can be done by immersing a substrate in the polymer solution, with consequent withdrawing, evaporation and drying. In a cast-coating technique, the polymeric solution will be cast onto the surface followed by solvent evaporation.

Surfactant-coated NPs provide special antistatic, stabilizing, antiviral coating properties for surface disinfection. Apart from coatings, NPs like AgNPs demonstrated antiviral effects including SARS-CoV-2 when applied in their nanopowder forms, which can also be applicable for face masks and air filters. Copper NPs had been proven for theirs antiviral effect against HCoVs by degrading and inactivating the viral genome which may be projected for use against the current pandemic, SARS-CoV-2. Recent studies also reported that CuNP-loaded surfaces can easily deactivate SARS-CoV-2 and be developed with less economy than AgNPs and with excellent stability. Furthermore, conjugation of CuNPs with quaternary ammonium structures exhibited enhanced antiviral activity. Replacing plastic and stainless steel materials with Cu alloy can limit COVID-19 risks.

Table 5 Nanobased Protective Equipment for COVID-19 Prevention

| S. No | NanoBased PPEs | Features of the Formulation | Reported Benefits of Nanobased PPE | Reference |
|-------|----------------|-----------------------------|-----------------------------------|-----------|
| 1     | Ag nanocluster/ silica composite facial masks | • Silver nanocluster/silica composite coating deposited on impregnated in facial masks | • Promising virucidal property, • Enhanced SARS-CoV-2 titer reduction, • Great safety to be used in crowded areas • Increased working life of filtering masks • Reduced waste production | 184       |
| 2     | Metal oxide nano-compounded hand sanitizer | • Nonalcohol-based neosporin, mupirocin, and tetracycline NPs blended with soap solution sanitizers | • Impart effective antiviral activity • Skin-friendly hand sanitizers | 185       |
| 3     | Zinc oxide nanospray | • Zinc (II) oxide NP (ZnO-NPs) used as a disinfectant nanospray | • High anti-SARS-CoV-2 activity at cytotoxic • Reduced host cellular toxicity • Elevated antiviral activity against SARS-CoV-2 | 186       |
| 4     | Silver NP (AgNPs)- based surgical masks | • Surgical masks by impregnating AgNPs | • Superior microbial reduction of 99.999% against a wide number of microorganisms. • Reusing surgical masks • Effective decontamination | 187       |
| 5     | Graphene nano based PPEs | • Coating onto fabrics such as face masks and gloves | • Excellent antimicrobial efficacy, • Providing both physical and chemical mechanisms of damage | 188       |
| 6     | Nanofiber membrane reusable masks | • Masks fabricated by melt blown fabrics and nanofiber membrane from spider-web bionic nanofiber membrane (nanocobweb-biomimetic membrane) | • Achieved the disinfection and reuse of masks • Can effectively alleviate the shortage of masks • Better repeatability and disinfection tolerance • High aerosol rejection efficiency | 189       |
spreading on surfaces. In another way, photothermal inactivation of SARS-CoV-2 from surfaces can be done by illuminating Ag and Au NPs and nanorods at an optimal wavelength to induce heating for viral inactivation. Encapsulating objects with photoactive nanomaterials and using electromagnetic radiation to disrupt SARS-CoV-2 cells are other methods for surface disinfection.

A study done by Abo-zeid et al showed that iron oxide NPs, both Fe$_2$O$_3$ and Fe$_3$O$_4$, can interact with viral spike protein destroying its ability of host cell attachment. In addition, they produced reactive oxygen specious (ROS) that inactivates SARS-CoV-2 in surfaces. Titanium dioxide (TiO$_2$) nanocoating is the other alternative for sanitizing public utilities and mass gathering areas. Due to its UV induced photocatalytic properties, it has an effective multidimensional application for decontaminating and minimizing the COVID-19 transmission. It is a convenient and cost-effect disinfecting approach, even for remote locations, through TiO$_2$-doped paints, air filtration aerosolized filters, TiO$_2$-impregnated ventilation systems, and Cu and Ag-loaded TiO$_2$ nanowires. Surfaces coated with aluminum alloy NPs also demonstrated an effective SARS-CoV-2 disinfection within six hours.

Physicochemical properties of graphene nanomaterials can be used to control the transmission of the COVID-19 pandemic by deactivating the virus from surfaces. Graphene and its derivatives inactivate the virus by exerting photothermal activities and binding to the viral S protein that results in inhibition of cellular interactions to the host cell receptors. Water treatment using nanostructures of light-activated, layered graphic carbon nitride disables the contaminating ability of viruses including SARS-CoV-2. Nanostructured anionic polymers showed pH adjusted, rapid and continuous disinfecting ability which can be a good alternative to inactivate the virus in a self-disinfecting manner. In recent times, nanobased air ionizers and surface purifiers that can be applied for decontaminating buildings and public offices are being studied and developed. Polymers can be awarded an antimicrobial effectiveness by covalent conjugation of biocidal agents such as quaternary ammoniums, phosphonium groups, chlorine dioxide, alcohols, and sulfonates to produce permanently coated, nonleaching sterile surfaces. Ventilator units can also be coated with the same principles to reduce the likelihood of COVID-19 infection and cross-infections.

**Nanotechnology for Improvement of Personal Protection Equipment (PPE)**

PPE includes textile materials such as headgear, goggles, masks, gloves, facial protection, and dresses or gowns. They are critical elements for protection from COVID-19
transmission. Nanostructures used in PPE modification are responsible to adsorb viral particles for viral inactivation and filtration efficiency which is the main principle for their application of COVID-19 prevention. The main challenges encountered by conventional PPE are associated with their poor antitoxicity, difficulty in breathability, heat dissipation, and reusability. Uncertainties are also rising on which, how, and how much they permit COVID-19 transmittability, especially in workplace settings and densely populated gathering areas which necessitates more trustworthy, cost-effective, efficient, and reusable PPE development. Appropriate understanding of the role and the usage of PPE by the health staff and the public and ensuring an adequate supply system are considerable factors for imminent prevention of the pandemic. That is why their application worldwide has not been enough to stop the transmission.

Environmental safety and waste management is another complicated issue during the pandemic season. It puts a substantial burden and results in a health compromising situation including carcinogenic health impacts questioning for other alternative technologies for the production of biomedical equipments and treatment of COVID-19 related wastes. Moreover, single-use PPE types become factors in environmental pollution and sources of biohazards. Not only the discarded PPEs, but also their derived decomposition products are threatening the aquatic organisms and human life that may persist for months.

Hasan et al revealed the potential long-term effects of these environmental impacts on aquatic ecosystems and human health as: physical effects (changes in microbiome, water quality deterioration, ecosystem alteration), physiological effects (reproduction hamper, oxidative stress, increased survival, metabolic damages), long-term effects (immunosuppression, carcinogenicity, genotoxicity, neurotoxicity). This indicates that advanced technologies for the development of eco-design approaches for PPE production are needed.

Nanostructures can impart their role by reducing single-use PPE by replacing them with novel reusable, self-cleaning, effective, and efficient antiviral products to minimize environmental challenges. This can be brought about by the application of antiviral NPs, nanofibers, and NP-coatings to acquire super-hydrophobicity, synergistic effects, self-cleaning functionalities with photothermal and photocatalytic sterilization. For these purposes, nanomaterials with intrinsic antiviral activity, such as AgNPs, graphene oxide (GO), CuO NPs, two-dimensional carbides, and nitrides that can capture and inactivate viruses are being investigated. Furthermore, a fluorescent NP penetrant inspection can be used for the detection of inner defects in used masks, to provide necessary data for the development of reusable masks, structural optimization, and evaluation standards. Less material consumption and reduced supply problems, efficient filtration due to large surface areas, cost-effective transmission control, and virus neutralization due to functionalization with chemically active groups are the main features of PPE modifications by using nanomaterials and nanotechnology.

Size- and time-dependent particle removal efficiency is reported from different protective respiratory masks which can be optimized by nanostructured systems. Ag nanocluster/silica composite nanocoating impregnated in facial masks possessed a promising virucidal property, reduced the SARS-CoV-2 titer, and provided great safety to be used in crowded areas. In addition, SiO₂ and Al₂O₃ NPs coated with polypropylene or polyethylene demonstrated super water repellent effects; TiO₂ and MgO NP coatings provided self-sterilizing activity; indium-tin oxide NPs produced an electromagnetic/infrared protective clothing and ceramic NPs resulted in an increased abrasion resistance. Generally, the mechanisms in these NP coating effects are reported to be surface oxidation, releasing free radicals or toxic ions, ROS generation, photoreaction, inhibition of viral interaction, entry and binding. Nanotechnology can also increase the filtration efficiency through improving viral particle capturing and retention, enabling rapid viral inactivation after capturing them, minimizing exhaled humidity effects on particle redistribution, and providing a very thin, high-efficiency reusable filtration media.

The application of nanofiber technology for face masks can reduce breathing resistance, maximize comfort by minimizing pressure, and provide enhanced filtration efficiency against very small viral particles (<50 nm). The Egyptians discovered a novel, reusable, recyclable, customizable, antimicrobial, and antiviral respirator facial mask feasible for mass production. The novel design is based on the filtration system composed of a nanofibrous matrix of polylactic acid and cellulose acetate containing CuO NPs and GO nanosheets produced by electrospinning technique. Nanofiber filter incorporated surgical masks showed a decrease in air-flow resistance, improved filtration efficiency, enhanced contaminant deactivation, and reduced risk of inhaling pathogens. Similarly, other PPE like gowns, facial shields, gloves, boots, and goggles can be
advanced with the aid of efficient and multifunctional nanostructures.61,79

Pharmacoeconomic and Regulatory Aspects

In the clinical trial of the COVID-19 vaccine, the two lipid mRNA-based vaccines, BNT162b2 and mRNA-1273, exhibited more than 95% efficacy, owing to their unique nanocarrier characteristics.224 Even though such effectiveness with reduced medicine intake and adverse effects can be achieved with nanomedicine, there is still a substantial concern on their toxicity. Moreover, the development of these nanostructured systems should be regulated as all marketing items must follow regulatory requirements.225,226 There is an international debate on the risk regulation of NPs. To resolve this controversy, uniform definitions of NPs are required for the identification and application of legal provisions to them and facilitate the marketing of nanotechnology-derived products. There should also be a validated method of analysis, detection, characterization, and complete information regarding the impact of nanomaterials as well as the assessment of nanomaterial exposure.227,228 The use of nanotechnology may result in significant problems, causing irreversible damage to the environment and humans, if adequate rules and legislation are not in place.229 The legal framework of nanotechnology was investigated to see if new regulatory action was necessary to address the hazards associated with nanomaterials. To take advantage from the benefits of nanoproducts, especially in severe pandemics like COVID-19, the public, customers, and employees need flexible and balanced regulatory actions based on scientific data. In addition, development of standards and guidelines on their preparation and use should be outlined to ensure safety and reduce the risk of liability.230

Authorization of substances and ingredients, qualification of hazardous waste, reinforcing conformity assessment methods, and restrictions on the entry of chemical substances and preparations to the market as well as their usage are all part of the nanomaterials regulation.227,230 Current regulatory frameworks cover a wide range of products and processes, including nanotechnologies, which implies that a separate regulator or regulatory framework may be unnecessary. However, some case studies suggest that the present framework should be modified because of the strange and uniqueness of NPs.230–232 Recent discoveries such as the NP-based COVID-19 vaccines, diagnostic, and therapeutic agents as well as PPE are now coming to support the globe’s fight against the pandemic. However, current regulations may not be sufficient to solve their risk management, production challenges, and market issues which necessitate working more on the nanoregulatory issues parallel to nanoproduct discoveries.228 Lack of understanding and communication about the science, use, and regulation of nanotechnology among all stakeholders hurts society perceptions and regulatory decision-making.233 Even though the risks posed by nanomaterials to the environment and humans have become a global concern, it is recommended for all relevant regulatory bodies to consider the impact of NPs in protecting humans from current and future pandemics such as COVID-19.234

Regarding the pharmacoeconomic aspects, there is a debate on the economic influence of nanotechnology. Reports are indicating that its short-term effect is minor, but it will provide a substantial economic impact in the long-term. Its prospective economic effects will be fully beneficial across the society and the spectrum of developed and developing countries. There was no evidence that nanotechnologies generate economic challenges that were notably different from those raised by other technological advancements.230,235 However, certain studies predicted that nanotechnologies can offer economic benefits, including the ability to create jobs, wealth, and well-being.236 These technologies are also shown to be a cost-effective option for many challenging medicine approaches.229 A pharmacoeconomic study would allow for the most efficient use of monetary resources and the maximum health return at the lowest possible cost. The high failure rate for innovative therapeutic compounds in the drug development cycle is mostly attributable to economic considerations to save resources.237 Such cost-based approaches have a significant impact on the development of nanotechnology-derived products and management strategies against the COVID-19 pandemic.224

Nanomedicines have the potential to make a significant contribution to inexpensive health care, but a rigorous evaluation through updated cost-effectiveness evaluations is required first. In global pandemic challenges, like the current COVID-19 pandemic, the success of introducing highly-priced and efficacious, yet costly, nanotherapies to market with their affordability can be considerably improved by using specific decision-making frameworks. The implementation of comprehensive, standardized cost-effectiveness studies can shift the focus to reducing health-care costs while maintaining care quality. One major flaw in current cost-effectiveness research in the field of nanomedicine is that, practically all studies focus solely on direct treatment costs, completely ignoring indirect
the importance of nanotechnology in the COVID-19 vaccine:

**Research and Patents**

Despite persisting for a very short time, there are many new investigations and patents related to COVID-19. From these patents, more than 10% are associated with “nano” topics including the use of different nanostructured systems for diagnostic, therapeutics, vaccination, and preventive approaches as nanocarriers, vectors, markers, filters, adjuvants, and intrinsic antimicrobials. Research and development is still underway on the effective application of nanomedicine with industrial implications to enhance safety, high sterilization capability with a low dosage, reusability, and eco- and user-friendly properties. Efficiently targeting antiviral nanocarriers and personalized therapy with precision nanomedicine are the near future perspectives of such investigations.

In summary, COVID-19 management can benefit from nanostructured delivery systems in that it can potentiate immune response modulations which may otherwise be difficult conventionally, possess precise targeting, reduce nontarget accumulation and associated toxicities, protect drugs and vaccines from degradation and inactivation in body environment, offer alternative vaccine delivery routes, and possess promising biodegradability and biocompatibility that can be controlled.

**Limitations and Challenges**

**Clinical Extrapolation**

With those vast advantageous outcomes, clinical translation of the nanoproducts has not yet been achieved. Unpredictable side effects, safety, and toxicity concerns, long-term fate, cost and complexity of NP preparations, need for pure study designs with acceptable sample sizes and validated methods are the persisting challenges. In contrast there are also probable limitations of the promising advantages of nanoformulations including difficulty to sterilize parenteral formulations suitably, biomolecule denaturation risks, low entrapment efficiencies, biodistribution profile characterization, off-target accumulations, and uncontrollable burst release effects.

**Disease and Pathogen Characterization**

The other vital issue is the lack of deepest understanding of the cellular, pathogenic and pathophysiologic aspects of SARS-CoV-2 and COVID-19 with the particular nanobiointerfaces involved in drug/vaccine development and delivery. SARS-CoV-2 also revealed different behaviors in different hosts which entails the need for the design of highly efficient nanosystems such as biomimetic organoids and organ-on-chips that can specifically assess and evaluate these behavioral variabilities. Even though the lungs are the best
targets in COVID-19 management, direct and targeted intra-nasal and pulmonary nanodeliveries are associated with severe impairment in respiratory sites and lung function. Further proof is needed to assure nanomaterial safety related to intolerable inflammation, cellular damage, fibrosis, small granulomatous lesions, geno-immunotoxicity, and oxidative stress due to abnormal NP accumulation in the alveoli which results in alveolar cell damage, blood vessel penetration, and then translocation to other organs. \(^\text{249–251}\) The design of such nanocarriers in such a way that the nanoformulation can escape the recognition by scavenger cells is also challenging and needs considerable effort before clinical translation. \(^\text{61}\)

### Large-scale Production

Scaling up, complicated fabrication process and only limited information on how and how much the NPs exert their impact on organisms with peoples’ reluctance to accept new technologies are other reported challenges. \(^\text{111}\)

### Regulation

Patent and intellectual property right issues remained challenging through this global pandemic era. The Open COVID Pledge requests patent and intellectual proprietors to voluntarily sacrifice the rights in helping the free fight during the crisis, but it is still being debated as it is dependent on the willingness of the patent holders. \(^\text{219}\) Moreover, regulatory issues are still far-away for the confidential application of nanomedicine with its full potentials. Ethical, scientific, biosafety and acceptance issues by regulatory agencies hinder nanomedicine to produce safe and high-quality nanodrugs including antivirals of this pandemic. \(^\text{9,135}\)

### Future Perspectives

#### Concerned Effort from the Pharmaceutical World

Having the opportunities and the challenges from nanotechnology, nanomedicine, and biotechnology in mind, the pharmaceutical society must put endless effort on investigating nanotherapies to manage COVID-19. Here, from the pharmaceutical point of view, searching for better antimicrobial/antiviral therapeutic agents with better efficacy and minimized adverse effects, optimizing dosages, and delivery systems for carriers and targets, investigating biocompatible, bio-functionalized, nanodrug loading systems; designing stimuli-responsive, immunosupportive, and immunomodulating agents by using nanopharmacology concepts, and developing personalized nanotherapeutics are based on variations of the effects of SARS-CoV-2 and patient-specific disease profiles. \(^\text{82}\)

### Multidisciplinary Research

The current pandemic crisis can be taken as a golden opportunity for the transformation of nanomedicine by intensifying the safety to risk ratio of nanostructures. For this to be true, in-depth investigational study, experience-sharing, and exchange of knowledge among different countries, different departments, and different companies including regulatory agencies are essential. \(^\text{9,176}\) Early stage regulatory guidelines with a mid and long-term research on positive opportunities and about factors that limit their applicability are needed. This can enable the global medical practice against the current and future pandemics. \(^\text{46}\)

### Combination of Technologies

Nanomedicine is now trying to combine the advance from machine learning, artificial intelligence (AI), and internet of medical things (IoMT) for modeling, encoding and interpreting cell-nanomaterial interactions which is crucial to forecast biosafety, predict efficacy, and formulate quantitative nanostructure activity-relationship (nano-QSAR). These combined applications can support the global struggle against COVID-19 by providing simplified data collection, mobile-sensing, as well as self-sampling of COVID-19 tests. Other related technologies such as robotics, telemedicine and 3D-printing can further complement the effective application of nanomedicine in fighting the pandemic. \(^\text{108,252}\)

### Conclusion

Even though the COVID pandemic is accelerating globally, there are still no approved drugs and internationally accepted free-access vaccines to counter its worldwide spread. Accurate prevention, rapid and early detection, effective immunomodulation, and definitive treatment strategies are not yet outlined. Nanostructured drug development and delivery-based research and development is now promising the world to end the pandemic effectively and shortly with radically modified therapeutic, diagnostic and prevention options. Should all regulatory, scale-up, and safety issues be settled, nanotechnology can guarantee the world for the current and the next unpredictable pandemic crisis. Extensive scientific research and collaborative multidisciplinary efforts are needed for its practically extrapolatable outcome.

### Abbreviations

ACE2, angiotensin converting enzyme-2; BBB, blood–brain barrier; CNS, central nervous system; COVID-19, coronavirus disease-2019; CPT, convalescent plasma therapy; CQ, chloroquine; DNA, deoxyribonucleic acid;
HCoV, human corona viruses; HCQ, hydroxychloroquine; IL, interleukin; LNP, lipid nanoparticle; NP, nanoparticle; PCR, polymerase chain reaction; PLGA, poly lactic-co-glycolic acid; POC(D/T), point-of-care (diagnosis/testing); PPE, personal protective equipment; RBD, receptor-binding domain; ROS, reactive oxygen species; RNA, ribonucleic acid; S, spike; SARS-CoV-2, severe acute respiratory syndrome – coronavirus – 2; VLP, virus-like nanoparticle; VLP, virus-like protein; WHO, World Health Organization.

Acknowledgments
Addis Ababa University and Bahir Dar University are thankfully acknowledged for giving us internet access.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. doi:10.1016/S0140-6736(20)30186-0
2. Perlman S. Another decade, another coronavirus. New Engl J Med. 2020;382(8):760–762. doi:10.1056/NEJMe2001126
3. Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-ncov and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.4
4. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689. doi:10.1016/S0140-6736(20)30260-9
5. Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;7:1–14.
6. Glebov OO. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. FEBS J. 2020;287:3664–3671. doi:10.1111/febs.15369
7. Ullah MA, Araf Y, Sarkar B, Moin AT, Rshad RA, Hasanur MD. Pathogenesis, diagnosis and possible therapeutic options for COVID-19. J Clin Exp Invest. 2020;11:em00755. doi:10.29333/jcxi/8564
8. Cardoso VMO, Moreira BJ, Comparetti EJ, et al. Nanotechnology helping in the fight against COVID-19. Front Nanotechnol. 2020;2:588915. doi:10.3389/fnano.2020.588915
9. Rai M, Bonde S, Yadav A, et al. Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints. Expert Rev Anti Infect Ther. 2020;1–10. doi:10.1080/14787210.2021.1836961
10. WHO. COVID-19 dashboard. Available from: https://covid19.who.int/. Accessed June 15, 2021.
11. Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569–576.
12. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10). doi:10.2807/1560-7917.ES.2020.25.10.2000180
13. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98. doi:10.1016/j.jare.2020.03.005
14. Cai J, Sun W, Huang J, Gamber M, Wu J, He G. Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020. Emerg Infect Dis. 2020;26(6):1343–1345. doi:10.3201/eid2606.200412
15. Chhantyal P. Cicada’s antimicrobial nanotechnology solution for COVID free surfaces; 2020. Available from: https://www.azonano.com/article.aspx?ArticleID=5621. Accessed June 12, 2021.
16. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi:10.1016/j.jhin.2020.01.022
17. Tong Y, Ruiqi RM, Leung D, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316
18. Sahu KK, Lal A, Mishra AK. Latest updates on COVID-19: a changing paradigm shift. J Med Virol. 2020;92(6):533–535. doi:10.1002/jmv.25760
19. Chaudhary V, Royal A, Chavali M, Yadav SK. Advancements in research and development to combat COVID-19 using nanotechnology. Nanotechnol Environ Eng. 2021;6(8). doi:10.1007/s41204-021-00102-7
20. Yang Y. Impact of the COVID-19 pandemic on biomedical and clinical research. Matter. 2020;3:970–973. doi:10.1016/j.matt.2020.08.026
21. Taylor JR, Skeate JG, Kast WM. Annexin A2 in virus infection. Front Microbiol. 2018;9:2954. doi:10.3389/fmicb.2018.02954
22. Vahedifar F, Chakravarthy K. Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. Emerg Mater. 2021;4:75–99. doi:10.1007/s42247-021-00168-8
23. Marzo T, Messori L. A role for metal-based drugs in fighting COVID-19 infection? The case of auranoitin. ACS Med Chem Lett. 2021;11:1067–1068. doi:10.1021/acsmedchemlett.0c00190
24. Terahl K, Baddal B, Gülcen HO. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: insights from a molecular mechanics-assisted structure-based virtual screening experiment. J Mol Graph Model. 2020;100:107697. doi:10.1016/j.jmgm.2020.107697
25. Seifi T, Kamali RA. Antiviral performance of graphene-based materials with emphasis on COVID-19: a review. Med Drug Discov. 2021;1:00009. doi:10.1101/j.meddisc.2021.100099
26. Ahmad MZ, Ahmad J, Aslam M, Khan MA, Alasley MY, Abdel-Wahab BA. Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. Nano Express. 2021;2:022007. doi:10.1088/2632-959X/abffed
27. Riva L, Yuan S, Yin X, et al. A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv. 2020; doi:10.1101/2020.04.16.044016
28. Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Discov. 2020;2(2). doi:10.4155/fdd-2020-0010
29. Picaud F, Herlem G. Hydroxychloroquine and azithromycin at odds with SARS-CoV-2 viral protein: a molecular dynamic study. *Asian J Nanomed Nanotechnol*. 2021;9(1):1061.

30. Lagier J, Million M, Gautret P, et al. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. *Travel Med Infect Dis*. 2020;36:101791. doi:10.1016/j.tmaid.2020.101791

31. Duverger E, Herlem G, Picaud F. A potential solution to avoid overdose of mixed drugs in the event of COVID-19: nanomedicine at the heart of the Covid-19 pandemic. *J Mol Graph Model*. 2021;104:107834. doi:10.1016/j.jmgm.2021.107834

32. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *Am. J. Ther.* 2021;28(4):e434–e460. doi:10.1097/MTJ.0000000000001402

33. WHO. “Solidarity” clinical trial for COVID-19 treatments: 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed June 16, 2021.

34. Yang D. Application of nanotechnology in the COVID-19 pandemic. *Int J Nanomedicine*. 2021;16:623–649. doi:10.2147/ijn.S296383

35. Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*. 2020;583(7815):290–295. doi:10.1038/s41586-020-2349-y

36. Wang CY, Li WT, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun*. 2020;11:251. doi:10.1038/s41467-020-16256-y

37. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Int J Nanomedicine*. 2021;16:6609–6611. doi:10.2147/ijn.S116621

38. Della-Torre E, Campaniacho C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. *Ann Rheum Dis*. 2020;79(10):1277–1285. doi:10.1136/annrheumdis-2020-21812213

39. Schrezenmeier E, Dormer T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol*. 2020;16(3):155–166. doi:10.1038/s41580-020-0372-x

40. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270. doi:10.1038/s41586-020-2012-7

41. Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. *Emerg Infect Dis*. 2020;26(5):908–924. doi:10.3201/eid2605.200151

42. Sagadevan S, Periasamy M. A review on role of nanotechnologies in drug delivery system. *Rev Adv Mater Sci*. 2014;36:112–117.

43. Aberoumandi SM, Mohammadhosseini M, Abasi E, et al. An update on applications of nanotechnology in cancer therapy. *Artif Cells Nanomed Biotechnol*. 2016;45(6):1058–1068. doi:10.1080/21691401.2016.1228658

44. Saravanan M, Mostafavi E, Vincent S, et al. Nanotechnology-based approaches for emerging and re-emerging viruses: special emphasis on COVID-19. *Microb Pathog*. 2021;156:104908. doi:10.1016/j.micpath.2021.104908

45. Yu Y, Bu F, Zhou H, et al. Biosafety materials: an emerging new research direction of materials science from the COVID-19 outbreak. *Mater Chem Front*. 2020;4:1930. doi:10.1039/D0MC00255K

46. Chauhan PS, Yadav D, Dubey A, Jin JO. Nano-biomaterials in sensing and therapeutic tool to mitigate viral pathogenesis with special reference to COVID-19. *Curr Pharm Des*. 2021;27: doi:10.2174/1381612827666210203142934

47. Hassanazadeh P. Nanotheranostics against COVID-19: from multi-valent to immune-targeted materials. *Control Release*. 2020;328:112–126. doi:10.1016/j.conrel.2020.08.060

48. Chan WCW. Nano research for COVID-19. *ACS Nano*. 2020;14(4):3719–3720. doi:10.1021/acsnano.9b08133

49. Kong XY, Sena-Torralba A, Alvarez-dieduk R, Muthosoamy K, Merkoçi J. Nanomaterials for nanotheranostics: tuning their properties according to disease needs. *ACS Nano*. 2020;14:2585–2627. doi:10.1021/acsnano.9b08133

50. Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *EMBO J*. 2020;39:e101511. doi:10.15252/embj.2020105114

51. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Nanoscale delivery: physicochemical and therapeutic aspects. *Int J Pharm*. 2007;337(1–2):1–24. doi:10.1016/j.ijpharm.2007.03.025

52. Kim M, Park J, Shon Y, et al. Nanotechnology and vaccine development: a review. *Asian J Pharm Sci*. 2014;9(5):227–235. doi:10.1016/j.aps.2014.06.002

53. Cao LZ, Wang ZS, Wang B. Application of nano biomaterials in antiviral vaccine adjuvant. *Chin J Appl Chem*. 2014;31(5):572.

54. Mamo T, Poland GA. Nanovaccinology: the next generation of materials science and engineering. *Vaccine*. 2012;30:6609–6611. doi:10.1016/j.vaccine.2012.08.023

55. Weiss C, Carriere M, Fusco L, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. *ACS Nano*. 2020;14:6383–6406. doi:10.1021/acsnano.0c03697

56. Huang H, Fan C, Li M, et al. COVID-19: a call for physical scientists and engineers. *ACS Nano*. 2020;14(4):3747–3754. doi:10.1021/acsnano.0c02618

57. Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic – a narrative review. *Anaesthesia*. 2020;75(7):920–927. doi:10.1111/anae.15071

58. Garai A, Gorai T. Improvement of personal protection for Covid-19 infection. *Int Res J Med*. 2020;02(06).

59. Third PS, Sareen A, Singh DD, Singh S, John S. Compromising situation of India’s bio-medical waste incineration units during pandemic outbreak of COVID-19: associated environmental-health impacts and mitigation measures. *Environ Pollut*. 2021;276:116621. doi:10.1016/j.envpol.2021.116621

60. Wang Z, An C, Chen X, Lee K, Zhang B, Feng Q. Disposable masks release microplastics to the aqueous environment with exacerbation by natural weathering. *J Hazard Mater*. 2021;417:126036. doi:10.1016/j.jhazmat.2021.126036
67. AkbariZadeh R, Dobaradar A, NabiPour I, et al. Abandoned Covid-19 personal protective equipment along the Bushehr shores, the Persian Gulf: an emerging source of secondary microplastics in coastlines. Mar Pollut Bull. 2021;168:112386. doi:10.1016/j.marpollbul.2021.112386

68. De-la-torre GE, Rakib R, Pizarro-Ortega CI, Dioses-Salinas DC. Occurrence of personal protective equipment (PPE) associated with the COVID-19 pandemic along the coast of Lima, Peru. Sci Total Environ. 2021;774:145774. doi:10.1016/j.scitotenv.2021.145774

69. Rakib R, De-la-torre GE, Pizarro-Ortega CI, Dioses-Salinas DC, Al-Najah S. Personal protective equipment (PPE) pollution driven by the COVID-19 pandemic in Cox’s Bazar, the longest natural beach in the world. Mar Pollut Bull. 2021;169:112497. doi:10.1016/j.marpollbul.2021.112497

70. Hasan NA, Heal RD, Bashar A, Haque MM. Face masks: protecting the wearer but neglecting the aquatic environment? - A perspective from Bangladesh. Environ Challenges. 2021;4:100126. doi:10.1016/j.envch.2021.100126

71. Rodríguez NB, Formentini G, Favi C, Marconi M. Environmental implication of personal protective equipments, in the pandemic era: LCA comparison of face masks typologies. Procedia CIRP. 2021;98:306–311. doi:10.1016/j.procir.2021.01.108

72. Ju JT, Boisvert LN, Zuo YY. Face masks against COVID-19: standards, efficacy, testing and decontamination methods. Adv Colloid Interface Sci. 2021;292:102435. doi:10.1016/j.cis.2021.102435

73. Mainardes RM, Diedrich C. The potential role of nanomedicine and research agenda to combating the SARS-CoV2 pandemic. Nanotechnol Appl. 2021;774:145774. doi:10.1016/j.sint.2021.07.001

74. Bhavana V, Thakor P, Singh SB, Mehra NK. COVID-19. Front Nanotechnol. 2021;9:100101. doi:10.3390/fnano.9010001

75. Rai M, Bondy S, Yaday A, et al. Nanotechnology as a shield against COVID-19: current advancement and limitations. Viruses. 2021;13:1224. doi:10.3390/v13071224

76. Gregory AE, Tritball R, Williamsen D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:152.

77. Lauster D, Klein K, Ludwig K, et al. Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry. Nat Nanotechnol. 2020;15(5):373–379. doi:10.1038/s41565-020-0660-2

78. Adhikari S, Adhikari U, Mishra A, Guragain BS. Nanomaterials for diagnostic, treatment and prevention of COVID-19. Appl Sci Technol Ann. 2020;1(1):155–164. doi:10.3126/asta.v1i1.30295

79. Jindal S, Gopinath P. Nanotechnology based approaches for combating COVID-19 viral infection. Nano Express. 2020;1:022003. doi:10.1088/2632-959X/ab7614

80. Singh A, Kumar M, Dubey AK. Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment. Med Devices Sens. 2021;4:e10140. doi:10.1002/mds.310140

81. Varahachalam SP, Lahooti B, Chaman M, et al. Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects. Int J Nanomedicine. 2021;16:539–560. doi:10.2147/IJNN.S283686

82. Tyagi PK, Tyagi S, Kumar A, Ahuja A, Gola D. Contribution of nanotechnology in the fight against COVID-19. Biointerface Res Appl Chem. 2021;11(1):8233–8241. doi:10.33263/BRIAC111.82338241

83. Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14(6):7617–7627. doi:10.1021/acsnano.0c0382277

84. Vashist SK. In vitro diagnostic assays for COVID-19: recent advances and emerging trends. Diagnostics. 2020;10(4):202. doi:10.3390/diagnostics10040202

85. Candanos MR. Here’s how nanoparticles could help us get closer to a treatment for COVID-19. 2020. Available from: https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/.

86. Chen Y, Miller A, Cao S, et al. Rapid escherichia coli trapping and retrieval from bodily fluids via a three-dimensional beaded stacked nanodevice. ACS Appl Mater Interfaces. 2020;12(7):7888–7896. doi:10.1021/acsami.9b13931

87. Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. Dual-functional plasmatic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. ACS Nano. 2020;14:5268. doi:10.1021/acsnano.0c02439

88. Chen YT, Kolhatkar AG, Zenasni O, Xu S, Lee TR. Biosensing using magnetic particle detection techniques. Sensors. 2017;17:2300. doi:10.3390/s17102300

89. Medhi R, Snino P, Ngo N, Tran H, Lee TR. Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater. 2020;3:8557–8580. doi:10.1021/acsanm.0c01978

90. Rodgers P. Nanoscience and Technology: Nature Publishing Group; 2020. 368. doi:10.1142/7439

91. Seo G, Lee G, Kim MJ, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(9):12257–12258. doi:10.1021/acsnano.0c076276

92. Alphandéry E. The potential of various nanotechnologies for coronavirus diagnosis/treatment highlighted through a literature analysis. Bioconjug Chem. 2020;31:1873–1882. doi:10.1021/acs.bioconjchem.0c00287

93. Baker AN, Richards SJ, Guy CS, et al. The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device. ACS Cent Sci. 2020;6(11):2046–2052. doi:10.1021/acscentsci.0c00855

94. Paliwal P, Sargolzaei S, Bhardwaj SK, Bhardwaj V, Dixit C, Kaushik A. Grand challenges in bio-nanotechnology to manage COVID-19 pandemic. Front Nanotechnol. 2020;2:5. doi:10.3389/ fnano.2020.571284

95. Gupta R, Sagar P, Priyadarshi N, et al. Nanotechnology-based approaches for the detection of SARS-CoV-2. Front Nanotechnol. 2020;2:589832. doi:10.3389/fnano.2020.589832

96. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822–3835. doi:10.1021/acsnano.0c02624

97. Chandra P. Miniaturized label-free smartphone assisted electrochemical sensing approach for personalized COVID-19 diagnosis. Sens Int. 2020;1:100009. doi:10.1016/j.sint.2020.100009

98. Nanotechnology Database. COVID-19 rapid test cassette. Available from: https://product.statnano.com/product/11669/covid-19-rapid-test-cassette. Accessed June 19, 2021.

99. Ubis I, International, Inc. FDA emergency use authorized. Smart detect SARS-CoV-2 RRT-PCR Kit/48. [online]; October, 2020. Available from: https://inbios.com/smart-detectsm-sars-cov-2-rrt-pcr-kit/. Accessed June 19, 2021.

100. Ahmed SR, Kang SW, Oh S, Lee J, Neethirajan S, Chiral zirconium dots: a new class of nanocrystals for optical detection of coronavirus. Helyon. 2018;4:e00766. doi:10.1016/j.helyon.2018.e00766

101. Broughton JS, Deng X, Yu G, et al. Rapid detection of 2019 Novel Coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay. medRxiv. 2020. doi:10.1101/2020.03.06.20032334
103. Chen Z, Zhang Z, Zhai X, et al. Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. *Anal Chem*. 2020;92:7226–7231.

104. Chacón-Torres CJ, Reinoso C, Navas-León DG, Briceno S, González G. Optimized and scalable synthesis of magnetic nanoparticles for RNA extraction in response to developing countries’ needs in the detection and control of SARS-CoV-2. *Sci Rep Nat Res*. 2020;10:19004. doi: 10.1038/s41598-020-75798-9

105. Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. *Theranostics*. 2020;10(13):5932–5942. doi:10.7150/thno.46691

106. Sharmiladevi P, Girigoswami K, Haribabu V, Girigoswami A. Nano-enabled theranostics for cancer. *Mater Adv*. 2021;2:2876. doi:10.1039/d1ma00069a

107. Siafaka PI, Okur NU, Karantzas ID, Okur ME, Gündogdu EA. Current update on nanofluids as therapeutic and diagnostic tools: a review for the materials used as nanoantherostics and imaging modalities. *Asian J Pharm Sci*. 2016;11:24–46. doi:10.1016/j.ajps.2016.03.003

108. Miyazawa T, Itaya M, Burdeos GC, Nakagawa K, Miyazawa T. A critical review of the use of surfactant-coated nanoparticles in nanomedicine and food nanotechnology. *Int J Nanomedicine*. 2021;16:3937–3999.

109. Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. *Nat Nanotechnol*. 2020;15(4):247–249. doi:10.1038/s41565-020-0674-9

110. Lammers T, Sofias AM, van der Meel R, et al. Dexamethasone nanomedicines for COVID-19. *Nat Nanotechnol*. 2020;15(8):622–624. doi:10.1038/s41565-020-0752-z

111. Lu H, Wang J, Wang T, Zhong J, Bao Y, Hao H. Recent progress on nanostructures for drug delivery applications. *J Nanomater*. 2016;Article ID 5762431, 12. doi:10.1155/2016/5762431

112. Ribeiro LNM, Fonseca BB. The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic. *Future Microbiol*. 2020;15(16):1571–1582. doi:10.2217/fmb-2020-0118

113. Molinano R, Pasto A, Taraballi F, et al. Biomimetic nanoparticles potentiate the anti-inflammatory properties of dexamethasone and reduce the cytokine storm syndrome: an additional Weapon against COVID-19? *Nanomaterials*. 2020;10.2031. doi:10.3390/ nano10112301

114. Tai T, Wu T, Wu H, et al. A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxochloroquine: a Non-clinical Pharmacokinetic Study. *Clin Transl Sci*. 2021;14(1):132–136. doi:10.1111/cts.12923

115. Morad R, Akbari M, Rezaee P, Koohachi A, Maaza M, Jamshidi Z. First principle simulation of coated hydroxochloroquine on Ag, Au and Pt nanoparticles. *Sci Rep Nat*. 2021;11:2131. doi:10.1038/s41598-021-81617-6

116. US. National Library of Medicine, ClinicalTrials.gov. Efficacy and safety of liposomal lactoferrin in COVID-19 patients with mild-to-moderate disease and in COVID-19 asymptomatic patients; May 14, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04475120. Accessed June 18, 2021.

117. Zhang Q, Honko A, Zhou J, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. *Nano Lett*. 2020;20(7):5570–5574. doi:10.1021/acs.nanolett.0c0278244

118. Mehranfar A, Izadyar M. Theoretical design of functionalized gold nanoparticles as antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *J Phys Chem Lett*. 2020;11:10284–10289. doi:10.1021/acs.jpcl.0c02677

119. ChemistryViews.org. Membrane-based ACE2-rich nanoparticles against COVID-19. Available from: https://www.chemistryviews.org/details/news/11293970/Membrane-Based_ACE2-Rich_Nanoparticles_against_COVID-19.html. Accessed June 18, 2021.
D’Arrigo JS. Nanotargeting of drug(s) for delaying Dementia: relevance of Covid-19 impact on Dementia. *Am J Alzheimers Dis Other Demen.* 2020;35:1–12. doi:10.1177/1533317520976671

Ritchie K, Chan D, Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage? *Brain Commun.* 2020;2(2):fcaa069. doi:10.1093/braincomms/fcaa069

Alamolhoda SZ, Zarghami N, Kahroba H, et al. Isothermal amplification of nucleic acids coupled with nanotechnology and microfluidic platforms for detecting antimicrobial drug resistance and beyond. *Adv Pharm Bull.* 2021;10:34172;aph.2022.004

Kusumoputro S, Tseng S, Tse J, et al. Potential nanoparticle applications for prevention, diagnosis, and treatment of COVID-19. *View.* 2020;1:20200105. doi:10.1002/VW.20200105

Tang Z, Zhang X, Shu Y, Guo M, Zhang H, Tao W. Insights from nanotechnology in COVID-19 treatment. *Nano Today.* 2021;36:101019. doi:10.1016/j.nanotoday.2020.101019

Hobson J, Savage A, Dwyer A, et al. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. *Nanoscale.* 2021;13:6410–6416. doi:10.1039/D1NR00309G

Vivekanandhan K, Shannugam P, Barabadi H, et al. Emerging therapeutic approaches to combat COVID-19: present status and future perspectives. *Front Mol Biosci.* 2021;8:604447. doi:10.3389/fmolb.2021.604447

Nikaeen G, Abbaszadeh S, Yousefinejad S. Application of nanomaterials in treatment, anti-infection and detection of coronavirus. *Future Med.* 2020;15:1743–5889.

Tai WB, He L, Zhang XJ, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell Mol Immunol.* 2020;17(6):613–620. doi:10.1038/s41423-020-0400-4

Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. *Nat Biotechnol.* 2007;25(10):1159–1164. doi:10.1038/nbt32293

Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol.* 2010;10(11):787–796. doi:10.1038/nri2688

Zeng C, Hou X, Yan J, et al. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. *bioRxiv.* 2020. doi:10.1101/2020.04.01.019877

Kaate S, Cinatl J, Doerr HW, Uberla K. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. *Virology.* 2007;362(1):26–37. doi:10.1016/j.virol.2006.12.011

Abdelatif AAH, Tawfeek HM, Abdel fattah A, Batiba GE, Hetta HF. Recent updates in COVID-19 with emphasis on inhalation therapeutics: nanostructured and targeting systems. *J Drug Deliv Sci Technol.* 2021;63:102435. doi:10.1016/j.jddst.2021.102435

Cocozza F, Piovesana E, Névo N, et al. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 spike protein-containing virus. *J Extracell Vesicles.* 2020;10(2):e12050. doi:10.1080/2165109X.2020.195258

Kim J, Mukherjee A, Nelson D, Jozic A, Sahay G. Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2. *bioRxiv.* 2020. doi:10.1101/2020.07.24.205583

Ting D, Dong N, Fang L, et al. Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. *ACS Appl Nano Mater.* 2018;1:5451–5459. doi:10.1021/acsanm.8b00779

Ansari MA, Almatroudi A, Alzohairy MA, et al. Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine–promising therapeutic strategy for SARS-CoV-2 treatment. *Expert Opin Drug Deliv.* 2020;17(12):1671–1674. doi:10.1080/17425247.2020.1813712

Yayehrad et al

153. Adeleye OA, Femi-Oyewo MN, Bamiro OA, et al. Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019. *Future J Pharm Sci.* 2020;7(72). doi:10.1101/s43094-021-00049-w

154. Karuppas V, Pillai P, Nair SV, Lakshmanan V. Comparison and existence of nanotechnology in traditional alternative medicine: an onset to future therapy. *Nanosci Nanotechnol.* 2018;8:13–25. doi:10.2174/2210681210606666106402004710

155. Alfaisal University, department of microbiology and immunology. Nature’s answer to Covid-19 treatment, 2021. Available from: https://www.timeshighereducation.com/hub/p/natures-answer-covid-19-treatment. Accessed June 16, 2021.
174. Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. *Vaccines*. 2021;9:359. doi:10.3390/vaccines9040359

175. Greinacher A, Thiele T, Warkentin TC, et al. Thrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination. *Res Sq*. 2021. doi:10.21203/rs.3.rs-362354/v1

176. Singh P, Singh D, Sa P, Mohapatra P, Khuntia A, Sahoo SK. Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. *Nanomedicine*. 2021;16(14):1219–1235. doi:10.2217/mm-2021-0004

177. WHO. COVID-19 vaccine tracker and landscape; June 18, 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed June 20, 2021.

178. Faciolià A, Visalli G, Laganà P, et al. The new era of vaccines: the “nanovaccination”. *Eur Rev Med Pharmacol Sci*. 2019;23:7163–7182.

179. de Vrieze J. Suscptions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions. Daily news on Science AAAS; December 21, 2020. Available from: https://www.sciencemag.org/news/2020/12/suscptions-grow-nanoparticles-in-pfizers-covid-19-vaccine-trigger-rare-allergic-reactions. Accessed July 20, 2021.

180. Dwivedi R. Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines. Posted in: Medical Research News | Disease/Infection News; March 15, 2021. Available from: https://www.news-medical.net/news/20210315/Research-looks-at-inflammatory-nature-of-lipid-nanoparticle-component-in-mRNA-vaccines.aspx. Accessed July 20, 2021.

181. Techno R. Understanding the nanotechnology in COVID-19 vaccines. Written for CAS, American Chemical Society; February 18. Available from: https://www.cas.org/resource/blog/understanding-nanotechnology-covid-19-vaccines. Accessed July 20, 2021.

182. Mortimer GM, Minchin RF. Nanotoxicology and nanovaccines. Elsevier Inc; 2017. Available from: https://espacelibrary.uq.edu.au/view/UQ:439461. Accessed July 20, 2021.

183. Zhao L, Setha A, Wibowo N, et al. Nanoparticle vaccines. *Vaccine*. 2014;32:327–337. doi:10.1016/j.vaccine.2013.11.069

184. Balagna C, Perero S, Percivalle E, et al. Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite surface. *Open Ceram*. 2020;1:100006. doi:10.1016/j.oceram.2020.100006

185. Ramaiah GB, Tegegne A, Melese B. Developments in nanomaterials and analysing its role in fighting COVID-19. *Mater Today*. 2021.

186. El-Megharbel SM, Alswat M, Al-Salimi FA, Hamza RZ. Utilizing of (zinc oxide nano-spray) for disinfection against “SARS-CoV-2” and testing its biological effectiveness on some biochemical parameters during (COVID-19 pandemic)—“ZnO nanoparticles have antiviral activity against (SARS-CoV-2)”. *Coatings*. 2021;11(4):388. doi:10.3390/coatings11040388

187. Valdez-Salas B, Beltran-Partida E, Nelson Cheng JSC, Valdez-Salas EA, Curiel-Alvarez M, Ibarra-Wiley R. Promotion of surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *Vaccine*. 2020;38(16):1564–1567. doi:10.1016/j.vaccine.2020.09.017

188. Warses SL, Little ZR, Keevil CW. Human coronavirus 229E remains infectious on common touch surface materials. *Mbio*. 2015;6(6). doi:10.1128/mBio.01697-15

189. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *New Engl J Med*. 2020;382(16):1564–1567. doi:10.1056/NEJMc2004973

190. Borkow G, Zhou SS, Page T, Gabbay J. A novel anti-influenza copper oxide containing respiratory face mask. *PloS One*. 2010;5(e11295. doi:10.1371/journal.pone.0011295

191. Sportelli MC, Longano D, Bonerba E, et al. Electrochemical preparation of synergistic nanoantimicrobials. *Molecules*. 2020;25:49. doi:10.3390/molecules25010049

192. Scully JR. The COVID-19 pandemic, Part 1: can antimicrobial copper-based alloys help suppress infectious transmission of viruses originating from human contact with high-touch surfaces? *Corrosion*. 2020;76(6):523–527. doi:10.5006/3568

193. Loeb S, Li C, Kim JH. Solar photothermal disinfection using broadband-light absorbing gold nanoparticles and carbon black. *Environ Sci Technol*. 2018;52:205–213. doi:10.1021/acs.est.7b04442

194. Nanografi Blog. *COVID-19 and nanotechnology*. Available from: https://nanografi.com/blog/covid19-and-nanotechnology/. Accessed June 15, 2021.

195. Abo-zeid Y, Ismail NSM, McLaren GR, Hamdy NM. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. *Eur J Pharm Sci*. 2020;153(153):105465. doi:10.1016/j.ejps.2020.105465

196. Dunnill CW, Parkin IP. Nitrogen-doped TiO2 thin films: photosensitization of gold nanoparticles and copper-based alloys help suppress infectious transmission of viruses originating from human contact with high-touch surfaces. *Environ Sci Technol*. 2020;44(19):100883. doi:10.1016/j.ejps.2020.100883

197. Al-Sayah MH. Chemical disinfectants of COVID-19: an overview. *J Water Health*. 2020;18(5):843–848. doi:10.2166/wh.2020.108

198. Laister D. Hull firm’s nanotech solution aims to stop COVID-19. *Daily news on the “nanovaccinology”*. Available from: https://www.businesslive.co.uk/enterprise/hullfirmsnanotechsolutionaims19352722. Accessed June 17, 2021.

199. Mouritz AP, Galos J, Linklater DP, et al. Towards antiviral polymer composites to combat COVID-19 transmission. *Nano Select*. 2021;1–11. doi:10.1002/nano.202100078

200. Nakamura S, Sato M, Sato Y, et al. Synthesis and application of silver nanoparticles (Ag NPs) for the prevention of infection in healthcare workers. *Int J Mol Sci*. 2019;20:3620. doi:10.3390/ijms20153620

201. Borkow G, Zhou SS, Page T, Gabbay J. A novel anti-influenza copper oxide containing respiratory face mask. *PloS One*. 2010;5(6):e11295. doi:10.1371/journal.pone.0011295

202. Sportelli MC, Longano D, Bonerba E, et al. Electrochemical preparation of synergistic nanoantimicrobials. *Molecules*. 2020;25:49. doi:10.3390/molecules25010049

203. Dunnill CW, Parkin IP. Nitrogen-doped TiO2 thin films: photosensitization of gold nanoparticles and carbon black. *Environ Sci Technol*. 2018;52:205–213. doi:10.1021/acs.est.7b04442

204. Nanografi Blog. *COVID-19 and nanotechnology*. Available from: https://nanografi.com/blog/covid19-and-nanotechnology/. Accessed June 15, 2021.

205. Abo-zeid Y, Ismail NSM, McLaren GR, Hamdy NM. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. *Eur J Pharm Sci*. 2020;153(153):105465. doi:10.1016/j.ejps.2020.105465

206. Dunnill CW, Parkin IP. Nitrogen-doped TiO2 thin films: photosensitization of gold nanoparticles and copper-based alloys help suppress infectious transmission of viruses originating from human contact with high-touch surfaces. *Environ Sci Technol*. 2020;44(19):100883. doi:10.1016/j.ejps.2020.100883
210. Peddinti BST, Downs SN, Yan J, et al. Rapid and repetitive inactivation of SARS-CoV-2 and Human coronavirus on self-disinfecting anionic polymers. Adv Sci. 2021;8(11):2003503. doi:10.1002/advs.202003503

211. Cavalcanti IDL, Nogueira MCBL. Pharmaceutical nanotechnology: products which are being designed against COVID-19? J Nanopart Res. 2020;22(276):10.1007/s11051-020-05010-6

212. Idumah CI. Influence of nanotechnology in polymeric textiles, applications, and fight against COVID-19. J Text Inst. 2020;1–21. doi:10.1080/00405000.2020.1858600

213. Ahmed MK, Afifi M, Uskoković V. Protecting healthcare workers from aerosol transmissions of COVID-19. Sensors. 2021;21:1567. doi:10.3390/s21051567

214. Wang D, Sun B, Wang J, et al. Can masks be reused after hot water decontamination during the COVID-19 pandemic? Engineering. 2020;6:1115–1121. doi:10.1016/j.eng.2020.05.016

215. Ramaiah GB, Tegegne A, Melese B. Functionality of nanomaterial and treating COVID-19. Mater Today. 2021. doi:10.1016/j.matpr.2021.04.306

216. Talebian S, Wallace GG, Schroeder A, Stellacci F, Conde J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat Nanotechnol. 2020;15:618–624. doi:10.1038/s41565-020-0751-0

217. Ahmed MK, Atif M, Uskoković V. Protecting healthcare workers during COVID-19 pandemic with nanotechnology: a protocol for a new device from Egypt. J Infect Public Health. 2020;13:1243–1246. doi:10.1016/j.jiph.2020.07.015

218. O’Dowd K, Nair KM, Forouzandeh P, et al. Face masks and respirators in the fight against the COVID-19 pandemic: a review of current materials, advances and future perspectives. Materials. 2020;13:3363. doi:10.3390/ma13153363

219. Khurana A, Allawadhi P, Khurana I, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2020;38(2021):101142. doi:10.1016/j.nantod.2021.101142

220. Peck LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915–928. doi:10.1016/j.addr.2007.05.017

221. Chen YC, Cheng H, Yang Y, Yeh M. Nanotechnologies Applied in Biomedical Vaccines. Intech. 2016;84–105. doi:10.5727/63453

222. Baran A. Nanotechnology: legal and ethical issues. Eng Manag Prod Serv. 2016;8(1):47–54. doi:10.1515/emj-2016-0005

223. Ridge SJ. A regulatory framework for nano technology. Naval Postgraduate School Monterey, California; 2018.1–55. Available from: https://sciencedo.com/downloadpdf/journals/emj/8/1/article-p47.xml. Accessed August 5, 2021.

224. Pandey G, Jain P. Assessing the nanotechnology on the grounds of costs, benefits, and risks. Beni-Suef Univ J Basic Appl Sci. 2020;9(63). doi:10.1016/s43088-020-00085-5

225. The Royal Society and the Royal Academy of engineering. Nanosci Nanotechnol. 2004;46(2004). doi:10.1007/s00234-004-1255-6

226. Fischer DB. Nanotechnology - scientific and regulatory challenges. Vil Environ L J. 2008;19(2):315.

227. Hamburg MA; Food & Drugs Administration. FDA’s approach to regulation of products of nanotechnology. Identifying nanomaterials for regulation. Science. 2012;336(6079):299–300. doi:10.1126/science.1205441

228. WHO. Nanotechnology and human health: scientific evidence and risk governance. ISEE Conference Abstracts, Vol. 1; 2014. doi:10.1289/isee.2014.p3-821

229. Piccetti D. Tiny things with a huge impact: the international regulation of nanomaterials. Mich J Environ Adm Law. 2018;7(2):447–478. doi:10.5281/zenodo.1288510

230. Orthen B. Nanotechnology: health and environmental risks of nanomaterials; 2007:1–65. Available from: www.baua.de/en/TopicsfromAtoZ/HazardousSubstances/Nanotechnology/Nanotechnology.html. Accessed August 5, 2021.

231. OECD International Futures Programme. Opportunities and risks of nanotechnologies. Report; 2007:46. Available from: https://www.oecd.org/science/nanosafety/44108334.pdf. Accessed August 5, 2021.

232. Morigi V, Tocchio A, Pellegrini CB, Sakamoto JH, Arnone M, Tasciotti E. Nanotechnology in medicine: from inception to market domination. J Drug Deliv. 2012;2012:1–7. doi:10.1155/2012/389485

233. Bosetti R, Marceffi W, Vereeck L. Assessing the need of quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies. Nanomedicine. 2013;8(3):487–497. doi:10.2217/nmm.13.15

234. Bosetti R, Jones SL. Cost-effectiveness of nanomedicine: estimating the real size of nano-costs. Nanomedicine. 2019;14(11):1367–1370. doi:10.2217/nmm-2019-0130

235. Bosetti R. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market? Nanomedicine. 2015;10 (12):1851–1853. doi:10.2217/nmm-15.15.74

236. Loubaton B. Exploring the quantitative dimensions of the economic impact of nanomedicine. European Technology Platform. (Online); 2012. Available from: https://www.nano.gov/sites/default/files/medicine_-_loubaton.pdf. Accessed August 5, 2021.

237. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multimodal failure: a narrative review on potential mechanisms. J Med Histol. 2020;51(6):613–628. doi:10.1016/s10735-020-09915-3

238. Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial pathway forward. Nat Nanotechnol. 2020;15:646–655. doi:10.1038/s41565-020-0737-y

239. Cagno V, Andreozzi P, D’Alicarnasso M, et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018;17:195–203. doi:10.1038/nmat5053

240. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano. 2020;14:7760–7782. doi:10.1021/acsnano.0c04006

241. Malabadi RB, Meti NT, Chalannavar RK. Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (COVID-19). JIRSL. 2021;8(2):ISSN 2321–2705. doi:10.25441/JIRSL.2021.8312

242. Liu K, Gu Z, Islam S, et al. Global landscape of patents related to COVID-19 vaccines. Adv Sci. 2020;7:1–21. doi:10.1002/advs.202003503

243. OECD International Futures Programme. Opportunities and risks of nanotechnologies. Report; 2007:46. Available from: https://www.oecd.org/science/nanosafety/44108334.pdf. Accessed August 5, 2021.
250. Hadrup N, Sharma AK, Loeschner K, et al. Pulmonary toxicity of silver vapours, nanoparticles and fine dusts: a review. Regul Toxicol Pharmacol. 2020;115:104690. doi:10.1016/j.yrtph.2020.104690

251. Nho R. Pathological effects of nano-sized particles on the respiratory system. Nanomed Nanotech Bio Med. 2020;29:102242. doi:10.1016/j.nano.2020.102242

252. Vafea MT, Atalla E, Georgakas J, et al. Emerging technologies for the study, diagnosis, and treatment of patients with COVID-19. Cell Mol Bioeng. 2020;13(4):249–257. doi:10.1007/s12195-020-00629-w